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Abstract 
Arsenic is a universal environmental toxicant associated mostly with skin related 
diseases in people exposed to low doses over a long term. Low dose arsenic 
trioxide (ATO) with long exposure will lead to chronic exposure.  Experiments 
were performed to provide new knowledge on the incompletely understood 
mechanisms of action of chronic low dose inorganic arsenic in keratinocytes. 
Cytotoxicity patterns of ATO on long-term cultures of HaCaT cells on collagen IV 
was studied over a time course of 14 days. DNA damage was also assessed. 
The percentages of viable cells after exposure were measured on Day 2, Day 5, 
Day 8, and Day 14. Statistical and visual analytics approaches were used for 
data analysis. In the result, a biphasic toxicity response was observed at a 5 
µg/ml dose with cell viability peaking on Day 8 in both chronic and acute 
exposures. Furthermore, a low dose of 1 µg/ml ATO enhanced HaCaT 
keratinocyte proliferation but also caused DNA damage. Global gene expression 
study using microarray technique demonstrated differential expressions of genes 
in HaCaT cell exposed to 0.5 µg/ml dose of ATO up to 22 passages.  Four of the 
up-regulated and 1 down-regulated genes were selected and confirmed with 
qRT-PCR technique. These include; Aldo-Keto Reductase family 1, member C3 
(AKR1C3), Insulin Growth Factor-Like family member 1 (IGFL1), Interleukin 1 
Receptor, type 2 (IL1R2) and Tumour Necrosis Factor [ligand] Super-Family, 
member 18 (TNFSF18), and down-regulated Regulator of G-protein Signalling 2 
(RGS2). The decline in growth inhibiting gene (RGS2) and increase in AKR1C3 
may be the contributory path to chronic inflammation leading to metaplasia. This 
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pathway is proposed to be a mechanism leading to carcinogenesis in skin 
keratinocytes. The observed over expression of IGFL1 may be a means of 
triggering carcinogenesis in HaCaT keratinocytes. In conclusion, it was 
established that at very low doses, arsenic is genotoxic and induces aberrations 
in gene expression though it may appear to enhance cell proliferation. The 
expression of two genes encoding membrane proteins IL1R2 and TNFSF18 may 
serve as possible biomarkers of skin keratinocytes intoxication due to arsenic 
exposure. This research provides insights into previously unknown gene markers 
that may explain the mechanisms of arsenic-induced dermal disorders including 
skin cancer.  
Keywords: HaCaT keratinocyte cell, chronic arsenic exposure, DNA 
damage, gene expression, visual analytics, cysteines residues, gene 
networks 
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Chapter 1 
Introduction 
1.1 Overview 
Arsenic (As) is an environmental toxicant and hazardous, naturally-occurring 
element widely distributed in the crust of the earth (Hall et al. 2006;IARC 
1987;Tchounwou et al. 2003). Due to its public health significance, arsenic is 
classified by the United States Environmental Protection Agency (Goering et 
al. 1999;U.S.EPA 2001) as a Group A carcinogen.  Human health effect 
caused by chronic exposure to low dose of arsenic through drinking water 
affect millions of people in more than 70 countries (IARC 2004). The adverse 
effects on health due to chronic arsenic exposure varies and may be 
influenced by the population groups, age, gender, cumulative dose of arsenic, 
nutritional status, genetic factors, lifestyle, individual susceptibility, and 
different chemical forms of arsenic in drinking-water (Ferreccio et al. 
2006;Kristiansen et al. 1997;Mitra et al. 2004). In the middle of the 19th century 
arsenic poisoning was a leading cause of death in South Africa (Copeman 
1940). Exposure to arsenic has been strongly associated with cancer in 
human and especially the skin cancer (Lynn et al. 1997;Schulz 1967). Apart 
from Australia, South Africa has the highest incidence of skin cancer in the 
world with more than 700 deaths each year (CANSA 2011). Though most of 
the cases in South Africa are associated with exposure to ultra violet (UV) 
radiation from the sun, the effect of secondary contact with arsenic cannot be 
totally ruled out. This is because in South Africa, high levels of arsenic have 
been found in the soils contaminated by the abandoned cattle tick dip 
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operations (Okonkwo 2007). In areas where water contamination with arsenic 
is endemic, exposure to low-dose arsenic over a long period of time leads to 
increased risk of developing epithelial cancers of the skin including 
intraepidermal carcinomas (Bowen disease) (Col et al. 1999), squamous cell 
carcinomas (SCC), basal cell carcinomas (BCC) (Yu et al. 1992), Merkel cell 
carcinoma (MCC) (Ho et al. 2005), and head and neck cancers seen mostly in 
alcoholics who are also exposed to arsenic (Bao et al. 2010). ATO is a multi-
site human carcinogen which targets the skin, (McNeely et al. 2006), bladder 
and kidney (Sasaki, Oshima, & Fujimura, 2007), liver (Liu et al. 2006), prostate 
and lung (Chen et al. 1996), bone marrow (myeloma), (Wang et al. 2006a), 
peripheral lymphocytes (Argos et al. 2006), neural tube (Wlodarczyk et al. 
2006), and urogenital cells (Su et al. 2006). Epithelial cancers of internal 
organs most often co-exist with cutaneous diseases such as arsenical 
keratosis, hyperpigmentation, and multiple cutaneous malignancies (Maloney 
1996;NEUBAUER 1947). Studies have shown that arsenic induces tumours of 
the liver, lung, ovaries and adrenal glands in other mammals as well (Waalkes 
et al. 2008). Aside cancers, other human diseases have been attributed to 
arsenic ingestion or inhalation. Such diseases include; hyperkeratosis and 
hyperpigmentation (Maloney 1996), black foot disease, atherosclerosis (Wang 
et al. 2006a), cerebral infraction (Chiou et al. 1997), hypertension (Chen et al. 
1996;Rahman et al. 2001), diabetes mellitus (Tseng 2008), skin lesions, liver 
injury and neurologic damage (peripheral neuropathy, encephalopathy, and 
intellectual deficits) in children (ATSDR 2007a;Wasserman et al. 2011). Also, 
ventricular fibrillation could be an outcome of arsenic poisoning (St et al. 
1970). Thus, public health concerns about long-term arsenic exposure have 
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arisen due to the increase in epidemiological reports of arsenic related cancers 
in different parts of the world including south-eastern Michigan, Taiwan, China, 
India and Bangladesh (McDonald et al. 2006;Mead 2005;Meliker et al. 
2007;Tchounwou et al. 2003). 
The mechanisms of arsenic toxicity and carcinogenicity have been reported on 
various cell types (Bae et al. 2002;Hamadeh et al. 2002;Rea et al. 2003) but 
the exact mechanism of arsenic-mediated carcinogenesis remains a subject of 
debate, with several lines of evidence supporting causes such as stimulation 
of cell proliferation (Chowdhury et al. 2010;Miller, Jr. 2002), alteration of DNA 
methylation, perturbation of signalling cascades (Chowdhury et al. 2010), 
oxidative stress and chromosomal aberrations (Kundu et al. 2011). There are 
also suggestions on disruption of transcriptional activity following arsenic 
exposure with extensive changes in global gene expression, and disruption of 
diverse regulatory mechanisms of gene expression (Das et al. 2011). 
Epigenetic dysregulation and arsenic metabolic activities involving human 
microbiome are currently stimulating the interest of researchers (Alava et al. 
2012;Betts 2011;Pinyayev et al. 2011;Van de Wiele et al. 2010;Wu et al. 
2011). 
Other scientific evidence tend to support the view that the breakdown of 
arsenic by human microbiota arsenic metabolizing organisms could be a 
plausible mechanism of action; this may directly or indirectly enhance or 
reduce the carcinogenicity of arsenic. Identifying the microbes isolated in both 
presence/absence of arsenic induced disease could be useful biomarkers in 
disease diagnosis. Furthermore, understanding the genetics of human 
4 
 
microbiome could be achieved with metagenomics techniques (Chauhan et al. 
2009;Chauhan et al. 2011;Gao et al. 2007). Such knowledge may explain why 
only some individuals who are exposed to environmental carcinogen, or 
carrying a genetic predisposition to cancer develop disease.   
A promising area of research for the discovery of arsenic mechanism of action 
and biomarkers of arsenic toxicity is genomics. Advances in the genomics and 
other “-omics” technologies are providing massive amounts of datasets and 
tons of scientific publications that describe potential gene, protein and 
biological processes as potential biomarkers of adverse health effects of 
environmental chemicals.  Toxicogenomics, a molecular technique applied in a 
whole-genomic capacity to investigate toxicant effects, is a recognized 
approach to discover potential biomarkers of toxicity and exposure biomarkers. 
Toxicogenomics could as well validate/quantify biomarker signatures (Afshari 
et al. 2011). The growth in data from toxicogenomics research has led to the  
development of bioinformatics databases such as the Comparative 
Toxicogenomics Database (CTD) for curating toxicogenomics relationships 
(chemical-gene, chemical-disease and gene-disease) found in scientific 
publications (Davis et al. 2011). As of the December 7, 2011, the CTD 
contained 28,413 PubMed references, 352,925 chemical-gene relationships, 
6,605 unique chemicals, 20,710 unique genes and   334 unique organisms. 
These toxicogenomics relationships and data when combined with biological 
information on human genes from other bioinformatics databases can lead to 
knowledge building (discovering previously unknown relationships from data) 
on potential biomarkers. Significant over-representation (enrichment) of certain 
biological topics for a gene is an example of biological information from a 
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bioinformatics database called ConceptGen (Sartor et al. 2010). The database 
currently consists of ~18,000 concepts, each with 5 or more assigned genes. 
Further, diverse bioinformatics tools are now available to reconstruct molecular 
interactions from predicted and experimentally validated data (Chautard et al. 
2011;Croft et al. 2011;Stark et al. 2006;Tarcea et al. 2009;Turner et al. 2010). 
The reconstruction of molecular pathways involving potential biomarker genes 
and proteins can also yield insights on how normal cellular activities are 
altered in different chemical exposures or disease conditions. These diverse 
datasets from bioinformatics databases therefore present opportunities for 
discovery and inferences on biological processes affected by arsenicals. It is 
of interest to identify genes for further research on mechanisms of toxic action 
and cancer initiation of arsenic on skin keratinocytes. 
 
1.2 Motivation 
Why arsenic? Arsenic is widely found in the environment and has been 
classified as a Group A carcinogen (U.S.EPA 2001) but there are still gaps in 
the precise mechanisms of arsenic-related carcinogenicity. Therefore, 
knowledge of the arsenic mechanism of action using gene expression models, 
gene networks and biological pathways perturbed by exposure to arsenic are 
important in terms of arsenic-related risk and exposure. Skin cancer is the 
most common arsenic-related cancer (Schwartz 1997;Smith et al. 1992). In the 
United States about 3,507,693   cases of non-melanoma skin cancer (NMSC) 
was reported in 2006, resulting in high morbidity and high cost of treatment 
(Rogers et al. 2010). Arsenic exposure has been closely linked to the 
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pathogenesis of multiple skin cancers (Yu et al. 2006). HaCaT keratinocyte 
cell line was selected for this in vitro research investigation because HaCaT is 
the first permanent immortalized epithelial cell line from adult human skin that 
exhibits normal differentiation and provides a promising tool for investigating 
the regulation of keratinization in human cells (Boukamp et al. 1988). The 
cultured HaCaT cell line was exposed to chronic low dose of arsenic in order 
to mimic the in vivo paradigm of chronic exposure in arsenic endemic areas 
(WHO 2001). This thesis research identified aberrations in gene expression 
and potential pathways that are part of the response after chronic exposure to 
ATO (after 22 passages). Also, time point cytotoxic effects of low dose chronic 
ATO exposure on HaCaT cells were studied to observe the patterns of toxicity 
after long-term exposure. Further understanding of the cytotoxic and genotoxic 
mechanisms of arsenic may provide more effective management of 
environmental exposure while also facilitating the discovery of biomarkers of 
arsenic induced cancer for effective diagnosis, prognosis and management of 
such cancers. 
  
1.3  Research Goal, Purpose, Hypothesis and Objectives 
The main goal of this research is to determine the mechanism of arsenic 
carcinogenesis in human skin epidermal keratinocytes. The purpose is to treat 
the skin cells with low dose ATO mimicking natural set up in endemic areas of 
arsenic poisoning through drinking water and determine the genomic changes 
that occur over a period of time. It is hypothesized that long-term, chronic 
exposure of human epidermal cells (HaCaT cells lines) to low dose arsenic will 
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lead to perturbation of cellular and molecular activities in keratinocytes. 
Knowledge of alterations in biological pathways affecting networks of the 
genes is crucial in understanding the mechanism of action of arsenic 
carcinogenesis in HaCaT cells.  
The following specific objectives were designed to test the hypothesis; 
1.) Determine cytotoxic and genotoxic effects of ATO on human 
skin keratinocytes (HaCaT cells) and Identify differentially 
expressed genes in HaCaT cells chronically exposed to low-
dose  ATO   
2.) Identify specific pathways from the gene expression datasets 
of HaCaT exposed to ATO.  
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Chapter 2 
2.0 Literature Review 
2.1 Arsenic species 
Arsenic compounds are divided into three major groups: inorganic arsenic 
compounds; organic arsenic compounds; and arsine gas (ATSDR 2010).  
They are further classified into four valence states namely; 0 oxidation state 
[AS(O), metalloid arsenic], trivalent, 3 oxidation state [AS(III), arsenites], 
pentavalent, 5 oxidation State [As(v), arsenate] and -3 oxidation state (arsine 
gas) (ATSDR 2007a;ATSDR 2010). The different arsenic species differ in their 
toxicity, biochemical and environmental behaviours (Alava et al. 2012;Gong et 
al. 2002). The most common arsenic species and their oxidation states are 
shown in Table 1. Arsenate [As (V)] is the most common environmental form of 
inorganic arsenic, but arsenite [As (III)] is more toxic and the most likely 
carcinogenic species (Bertolero et al. 1987;Lerman et al. 1983;Tinwell et al. 
1991). 
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Table 1: Arsenic Compounds of Environmental and Human Relevance* 
Trivalent oxidation 
state  
[As(III), or As(+3)]                   
Abbreviatio
ns 
Formula Pentavalent oxidation 
state  
[As(V), or As(+5)] 
Abbreviatio
ns 
Formula 
      
ATO     As
III
 As2O3 Arsenic pentoxide As
V
 As2O5 
      
Arsenite, arsenous 
acid 
As
III
 As(OH)3                        Arsenate, arsenic acid As
V
 AsO(OH)3 
Monomethylarsono
us acid   
[MMA(III)]           CH3As(OH
)2 
Monomethylarsonic acid MMA
V
 CH3AsO(OH)2 
Dimethylarsinous 
acid     
DMA
III
 (CH3)2AsO
H 
Dimethylarsinic acid 
(Cacodylic acid) 
DMA
V
 (CH3)2AsO(OH
) 
Trimethylarsine TMA
III
 (CH3)3As Trimethylarsine oxide TMAO (CH3)3AsO 
Arsenic trichloride  AsCl3 Monomethylmonothioarsen
ate 
MMMTA
V
 CH3AsO2S
−2
 
   Arsanilic acid (p-
aminophenylarsonic acid 
p-AsA H2NC6H4AsO3
H2 
   Arsenobetaine  C5H11AsO2 
   Lead arsenate LA PbHAsO4 
   Calcium arsenate  (Ca3(AsO4)2 
* Arsenic compounds can be classified into three major groups: inorganic arsenic compounds; 
organic arsenic compounds 
 
2.2 Routes of Exposure 
Arsenic is released from both natural and anthropogenic sources. 
Environmental arsenic contamination occurs from industrial smelting of metals, 
power generation with coal, and applications of pesticides and herbicides 
(NEUBAUER 1947;USEPA 2006).  
Human exposure occurs mainly through, food, water, air and soil as well as 
the natural accumulation of soil arsenic into grains, vegetables, fish, and 
meats (ATSDR 2007a;Hughes et al. 2011;Liu et al. 2010). Arsenic may enter 
the organism by dermal contact, inhalation, or ingestion of contaminated 
drinking water, foodstuffs or medication (IARC 1998). Understanding the 
environmental levels of arsenic that can cause a public health concern is 
crucial in planning mitigation strategies 
. 
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2.2.1 Arsenic contamination of Drinking Water 
The main source of high exposure of general population to arsenic compounds 
is water (Liu et al. 2010). The United States (U.S.) Public Health Service and 
the World Health Organization have set the guideline for arsenic in drinking 
water as 10µg/l but in endemic developing countries arsenic drinking water 
standards is relaxed to 50µg/l (Petrusevski et al. 2008;Smith et al. 2004). High 
arsenic levels have been detected in groundwater of different parts of the 
world, (Nordstrom 2002). Bangladesh and West Bengal (India) are the most 
affected areas of the world with arsenic concentration in groundwater in some 
area up to 3200 μg/L (Chakraborti et al. 2010;Chakraborti et al. 2011). The 
inorganic form of arsenic is the most common found in water. It can be stable 
as both arsenite and arsenate inorganic arsenicals (Khan et al. 2006;Saxe et 
al. 2007). Arsenite is the most prevalent species in the groundwater while 
arsenate species more significant in the surface water of the rivers (Pandey et 
al. 2006). The major source of arsenic in underground water is through the 
reductive dissolutions of arsenic-rich Fe (III) oxyhydroxides and/or al-
hydroxides present in aquifer. Other processes that introduce arsenic into 
underground water may include oxidation of aquifer arsenical pyrite and other 
arsenic-bearing sulphide minerals, and the exchange of adsorbed arsenic with 
other competitive anions (phosphate, bicarbonate and silicate) (McArthur JM 
2001;Nickson RT 2000;Pandey et al. 2006). In a U.S. Geological Survey 
(USGS) report, the median ground water concentration was estimated to be 1 
μg/L or less, with much higher levels in some groundwater aquifers, 
particularly in the western U.S. such as Nevada which have median levels of 
about 8 μg/L (Focazio 1999). High natural occurring arsenic levels of up to 
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1,000μg/L have been reported in the U.S. in drinking water (Lewis et al. 
1999;Steinmaus et al. 2003). The shallow ground water of the western United 
States, Arizona, Utah, Nevada, California and Washington in particular are 
hotspots for arsenic contamination (Twarakavi 2006). In a research conducted 
in Bangladesh, a range of 0.05 to 2.50 µg/ml arsenic levels in drinking water 
was reported (Anawar et al. 2002) and concentrations of up to 3.4 µg/ml of 
arsenic were recorded in drinking water source in West Bengal, India (Guha 
Mazumder et al. 1998). 
 
2.2.2 Arsenic food contamination 
In the mid-19th century, arsenic was intentionally added to food as a 
preservative prior to the discovery of its deleterious effects on human health 
(Hughes et al. 2011). Food especially seafood has proven to be a major 
source of arsenic exposure to human (Uneyama et al. 2007). In a survey of 
heavy metals in commercial fish in New Jersey, USA, arsenic levels in fish 
including Chilean sea bass, croaker, flounder, porgie, and whiting exceeded 
the U.S. Environmental Protection Agency (EPA) regulatory limit by 1.3 µg/ml 
(Burger et al. 2005). Apart from drinking water, diet is a major source of both 
inorganic and organic arsenic and estimates of dietary inorganic arsenic 
intakes vary. Arsenic could enter the food cycle by growing the crop on arsenic 
contaminated soil or by irrigating the farm with arsenic contaminated water 
(Das et al. 2004). At a rice paddy in Bangladesh, rice grain grown in soil with 
high arsenic concentrations resulted in rice grain samples with arsenic levels 
above 1.7 µg/g dry weight (Meharg et al. 2003).  In the U.S., estimates indicate 
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that adults and children consume an average of 3.2μg/day with a range of 1-
20μg/day (Cullen et al. 1995;Schoof et al. 1999). The estimated arsenic daily 
intake in Europe by the European Food Safety Authority is 0.13 to 0.56 
μg/kg/day for average consumers and 9.1 to 39.2 μg/day for a 70-kg adult 
(EFSA 2009) with respect to the ratio of inorganic arsenic to total arsenic in 
food. In India, it was observed that cooked foods had higher levels of arsenic 
than raw foods.  Daily dietary intakes of arsenic from the foodstuffs for adults 
were from 171.20 - 189.13 μg/day, while the range for children was 91.89 - 
101.63 μg/day (Roychowdhury et al. 2002).  
 
2.2.3 Arsenic from the Soil  
The natural content of arsenic in soils globally ranges from 0.01 to over 600 
mg/kg, with an average of about 2 to 20 mg/kg (Kabata-Pendias A 1992;Yan-
Chu 1994). The major source of arsenic in soil is the parent rock from which 
soils are formed, and thus the lithology of parent rock materials, volcanic 
activity, bioactivity, weathering history, transport, sorption, and precipitation all 
contribute to the nature of arsenic in soil (U.S.EPA 1987). The 
biotransformation of arsenic species mainly occur in the soil and the three 
major modes of biotransformation observed include: the biosynthesis of 
organoarsenic compounds, redox transformation between arsenite and 
arsenate, and the reduction and methylation of arsenic (Andreae et al. 1983). 
Arable lands could be contaminated with arsenic from run-off water and the 
use of arsenic-rich ground water for irrigation (Meharg et al. 2003;Saha et al. 
2007). A nationwide survey in the U.S. conducted in areas perceived to have 
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no anthropogenic sources of arsenic reported a natural background 
concentrations in soil ranged from < 1 to 97 mg/kg (Shacklette 1984). In South 
Africa, elevated total arsenic levels (1,033–1,369 µg/ml) were detected in the 
soils contaminated by historically cattle tick dip operations (Okonkwo 2007). 
The greatest arsenic value (1,369 µg/ml) was obtained at the surface, 
indicating that arsenic was still abundant at the surface even though the dip is 
no longer in operation (Moremedi 2007). Inorganic arsenic is the major form of 
arsenic in soil but high levels of organic forms are also seen in soils. However, 
pentavalent arsenic is more commonly seen in soil as trivalent arsenical are 
easily oxidized (Gong et al. 2002). Major contributors of arsenic to the soil are 
anthropogenic activities such as mining manufacturing activities, and 
application of arsenic-containing pesticides (Roberts et al. 2002). High soil 
arsenic are seen at mine tailings, smelter facilities, cattle dip sites, electric 
substations, wood treatment (chromated copper arsenate) sites, pesticide 
treatment areas, railroad rights-of-way, golf courses, and dumps (Roberts et 
al. 2002). Although exposure to soil arsenic could be via inhalation of soil 
particles blown by wind and dermal absorption, the amount of arsenic in 
ambient air is low; also, arsenic is poorly absorbed through the skin from the 
soil (U.S.EPA 2001).  Thus, incidental ingestion is the main source of 
exposure to arsenic in soil but when compared with the other natural routes of 
exposure, the amount of arsenic from soil is far less than the amount from 
drinking water and diet (Boyce et al. 2010). This is likely because there is 
reduced amount of inorganic arsenic as well as reduced bioavailability of 
arsenic in soil compared to water (Roberts et al. 2002).   
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2.2.4 Arsenic from the air  
Inorganic arsenic is the major form of arsenic found in air and it is very low in 
concentration, contributing to less than 15% of arsenic exposure when 
compared to arsenic exposure from food, water and soil (EC 2000;U.S.EPA 
1999). The concentration of arsenic in air due to non-human activities ranges 
from 1 to 3 ng/m3, and the range of the concentration in urban areas is 20 to 
100 ng/m3 (ATSDR 2007b). According to the European Commission (EC 
2000) reports, the range of arsenic in air are; 0-1 ng/m³ in remote areas, 0.2-
1.5 ng/m³ in rural areas, 0.5-3 ng/m³ in urban areas, and up to about 50 ng/m³ 
at industrial sites. Anthropogenic activities such as combustion processes 
introduce highly soluble arsenic oxides into the air which are circulated by the 
wind and returned to the earth in wet or dry deposition. Also, output gas from 
power plants using coal and oil which naturally contain arsenic may 
contaminate the atmosphere with arsenic (Pacyna JM. 1987).  
 
2.2.5 Arsenic in medication 
Although historically, arsenic was considered a poison (Gallagher 1998), its 
use in the treatment of various ailments dates back to more than 2400 years 
ago. There are references suggesting its application as medication for the 
treatment of many diseases such as toothaches, ulcers and abscesses 
(Antman 2001;Hyson, Jr. 2007;Jolliffe 1993;Riethmiller 2005;Waxman et al. 
2001). Fowler's solution which consists of 1% solution of potassium arsenite 
was discovered in 1786 and was effectively used to treat malaria, syphilis, 
asthma, chorea, eczema, and psoriasis (Cuzick et al. 1992;Scheindlin 2005). 
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Fowler’s solution was also used in leukaemia patients to lower white blood cell 
count (Antman 2001) and as a tonic for anaemia. It was used to treat 
rheumatism, dermatitis herpetiformis, Hodgkin’s disease, pemphigus and 
pernicious anaemia (Jolliffe 1993). An organic arsenical, salvarsan was 
introduced in 1910 by Paul Ehrlich for treating syphilis and trypanosomiasis 
(Aronson 1994;Riethmiller 2005). In September 2000, United States Food 
Drug Administration (FDA) approved the use of ATO for the treatment of 
relapsed or refractory acute promyelocytic leukaemia (APL) cases resistant to 
all-trans retinoic acid (ATRA) (Ablain et al. 2011;Antman 2001;Rust et al. 
2001;Zhang et al. 2001). A better understanding of arsenic mechanism of 
action has led to increase in clinical trials undertaken to determine the 
therapeutic effect of ATO on other types of cancers such as non-APL acute 
myeloid leukaemia and myelodysplastic syndromes (Murgo 2001;Sekeres 
2007). There are also on-going research on the combination of ATO with other 
agents such as vitamin C (ascorbic acid) for the treatment of 
lymphoproliferative disorders (Hussein 2001) and multiple myeloma (Munshi et 
al. 2002). ATO was the drug of choice before the discovery of metronidazole in 
1959 for the treatment of Trichomona vaginalis infection (trichonomiasis) which 
causes vaginal discharge (Forgan 1972;Jolliffe 1993). In traditional Chinese 
medicine, arsenic derivatives are still used to benumb the pulp of a painful 
tooth (Miller, Jr. et al. 2002). Organic arsenic compound, Melarsoprol, is still 
the drug of choice for the treatment of the protozoan parasite, trypanosomiasis 
(Bisser et al. 2007).  
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2.2.6 Occupational Arsenic Exposure 
Arsenic is as an essential ingredient in the manufacturing of a wide variety of 
products, including wood preservatives, herbicides, insecticides, pesticides, 
fungicides, high-emitting diodes, and semi-conductors. This makes workplaces  
sources of inhalation of and dermal exposure to arsenic (ATSDR 2007b). 
Arsenic was first used for tick control in South Africa in 1893 and since then, 
over a thousand cattle dipping vats were constructed throughout the country 
where arsenic was applied as the sodium salt of arsenous acid (Wagner et al. 
2003). High arsenic levels were found in mining environments and abandoned 
metal ores because as arsenic is released during the smelting process and 
coal burning, the resulting stack dust and flue gas contaminate the soil and 
water with arsenic (Bhumbla 1994). Workers at such places are exposed to 
arsenic mainly by inhalation of arsenic dust or from ATO vapours. The uptake 
of airborne arsenic could be influenced by arsenic compound characteristics, 
matrix composition, and particle size distribution (Yager et al. 1997). Cullen, 
2005 reviewed arsenic toxicity due to inhalation of airborne arsenic from wall 
papers which contained arsenic dyes in the form of Paris green or copper 
acetoarsenite (Cullen 2005;Scheindlin 2005). Hughes, in their 2011 review 
article reported that lead arsenate which was used as a pesticide for apple and 
cherry orchards was discontinued in 1988 by the U.S. government because 
orchard farmers were getting sick and there was concern that fruits may also 
have arsenic residues (Hughes et al. 2011;Wagner et al. 2003). Studies on the 
orchard workers later provided a basis for understanding some of the long-
term effects of occupational exposure to arsenic. However, occupational 
exposure through inhalation studies in the copper smelting industry was used 
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to establish definitive links between arsenic, (a by-product of copper smelting), 
and lung cancer (Enterline et al. 1995;Hughes et al. 2011;Mabuchi et al. 
1980;Nelson et al. 1973;Tollestrup et al. 1995). The high lung cancer mortality 
observed among miners was related to the estimated average intensity of 
exposure to arsenic but not to the duration (Jarup et al. 1989;Pinto et al. 
1977). Another research at a Smelter environment in Sweden described 
chromosomal aberrations in workers exposed to arsenic (Nordenson et al. 
1978). Dermal and neurological effects were also increased in some of these 
studies. Increased vasospastic reactivity in the fingers and Raynaud's 
phenomenon in smelter workers seems to be due to functional alterations in 
the vessels caused by inhalation of arsenic (Lagerkvist et al. 1986). Lagerkvist 
and co-workers concluded that peripheral vascular disturbances caused by 
arsenic are dependent on long-term arsenic exposures and are independent of 
short-term fluctuations in arsenic exposure (Lagerkvist et al. 1988).  
Although the use of some arsenic based pesticides such as lead arsenate has 
been discontinued, the vast land mass formerly used as orchards in New 
Jersey, Washington and Wisconsin may still be contaminated with lead 
arsenate (Hood 2006). Inorganic arsenic base pesticides are currently being 
replaced by organic arsenicals including monosodium methanearsonate 
(MSMAsV) and dimethylarsinic acid (DMAsV), also known as cacodylic acid 
because they are less toxic than inorganic arsenicals (Cohen et al. 
2006;Steinmaus et al. 2010). With the association of arsenic exposure to 
occupational health defects, it is very necessary that the industries establish 
effective environmental safety measures to protect their workers and the 
environment.  
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2.3 Arsenic mechanism of action 
Mechanisms of action of arsenic in humans have been described as 
summarized in Figure 1 and Table 2. The previously suggested mechanisms 
with the addition of the interaction between pre-systemic arsenic and human 
resident microbial flora are briefly reviewed. 
 
 
Figure 1: Proposed Modes of Action of Arsenic 
 
19 
 
Table 2: Modes of action for arsenic and associated biochemical effects 
Mode of action  Biochemical effects References - PubMed 
Identifiers 
(PMID) * 
 Human microbiome 
interaction 
Intestinal microbiome arsenic methylation 
 
20603239, 21807598, 
21388151, 21905058 
Perturbation of keratin 
expression 
Cell growth, differentiation and maturation distortion,  19524636, 19776502, 
19524636,1717607,5644201, 
7689238, 19524636,18572023 
Genotoxicity 
 
Chromosomal aberration, genomic instability,  
↓dose = aneugen, ↑dose = clastogen 
p53 dysfunction 
21461292,21035470, 
8993795,17450239, 9380733  
Cellular immune 
dysfunction  
↓CD4+ cells 
 
16807664, 10967126, 
Sulphur interaction Arsenic-thio interaction disrupts protein conformations 1641401, 20981267 
Induced Cell 
proliferation 
Cyclin-dependent kinase 4 (CDK4),  
↑ Transcription factor 1 (E2F1) 
↑Granulocyte macrophage-colony stimulating factor (GM-
CSF) 
↑Transforming growth factor-alpha (TGF alpha) 
20016248, 20654705, 
8917704, 11312651 
Phosphate interaction Form unstable arsenoesters with hydroxyl group, 
Uncouple formation of ATP via Asenolysis 
15257611, 21357385, 
21266531, 19478237 
Epigenetic 
dysregulation 
 
Altered histone acetylation, miRNA expression, 
methylation, and phosphorylation 
18448484, 15313424, 
20682481, 14732866, 
19707557, 20461219, 
22072212 
Signal transduction 
 
Activation of mitogen activated protein kinase pathway, 
JNK phosphatase & NF-κB dysfunction 
 
20339924, 20654705, 
10967126, 19524636, 
14971646, 16807664, 
11312654, 12076506 
Altered DNA 
Methylation 
 
Inhibition of DNA ligase & polymerase β 
Altered SAM metabolism 
Hypomethylation = overexpression of oncogenic genes 
18448484, 20682481, 
14580687, 17050553, 
12569548, 12377979, 
9380733, 12426129   
Reactive oxygen 
species induction 
↑H2O2, O2, ROO, OH, NO 
↓ Glutathione (GSH) 
12482246,15257611, 
19203718, 16807664 
Cocarcinogen Enhanced mutagenicity of UV, X-rays & Chemicals 15276419, 17316729 
* Citation for PubMed can be obtained from http://www.pubmed.gov 
 
2.3.1 Perturbation of Keratin Expression 
The expression of cytokeratins (CK) in HaCaT keratinocytes is impaired by 
chronic arsenic exposure. Aberrant and progressive alterations CK expression 
is a common feature observed in human skin lesions, including hyperkeratosis 
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and squamous cell carcinoma (SCC) (Markey et al. 1991;Sun et al. 
2009;Tseng et al. 1968). Thus, the expression of simple epithelial keratins 
could be used as a biomarker for monitoring malignancy of keratinocytes and 
determine tumour invasion and/or changes in epithelial-mesenchymal 
interactions (Leigh et al. 1993;Markey et al. 1991). Keratins are the major 
abundant and structural proteins of the epidermal layer of epithelial cells 
(Coulombe et al. 2002). Keratins primarily maintain the structure of epithelial 
cells and protect the cells from mechanical and non-mechanical traumas that 
may cause cell death (Sun et al. 1983). They may also be involved in signal 
transduction between adjacent cells, and could serve as markers for different 
stages of epithelial differentiation (Markey et al. 1991;Perkins et al. 1992). 
Keratins are intermediate filament proteins found in the skin, nails and hair. 
There are two major subgroups; the epithelial cytokeratin (CK type I), and 
trichocyte (hair/hard, type II) keratins (Rugg et al. 2004). Cytokeratins are 
located in the cytoplasm and are so named to differentiate them from 
specialized keratins found in the nails, and hairs (Jacques et al. 2009). Tissue-
specific and cell-specific differentiation of epithelial cells is closely linked with 
the expression of keratin intermediate filaments. Also, because the 
intermediate filament types are largely conserved during malignant conversion, 
their expression in a tumour can be used to identify its origin (Osborn et al. 
1982). The suggested role of increased expression of CK in arsenic 
carcinogenesis of skin may be exacerbated by an increase in the expression 
of other proteins such as matrix metalloproteinase-9 secretion (MMP-9), an 
enzyme often secreted by cancer cells to help invade through the local extra-
cellular matrix (Pi et al. 2008;Sun et al. 2009). The transcripts of various 
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keratin genes used as markers of different stages of cell differentiation are 
increased in arsenic- treated HaCaT cells. These include CK1, associated with 
hyperkeratosis, CK10, a biomarker of dermal cancer progression and always 
co-expressed with CK1, CK13, CK8 and CK18 (Markey et al. 1991). Other 
keratins affected by arsenic include differentiation marker genes in simple 
epithelial tissues which are the earliest keratin genes expressed during 
embryogenesis, filaggrin (linked to proliferation) (Winge et al. 2011), involucrin 
(an early differentiation marker) and loricrin (late differentiation gene), CK6 
(induced in response to stressful stimuli, such as wounding), and CKs 6/16 
and 7/17 (stress response, adaptive response to arsenic)  (Jacques et al. 
2009;Sun et al. 2009).  
 
2.3.2 Genotoxicity 
Gene expression studies are promising areas of demonstrating genotoxic 
effect of arsenic on exposed human cells. Because gene expression is a 
tightly regulated process, it could be relied on to measure the response of cells 
to environmental stimuli and to its changing needs. Many diseases have been 
linked to disruptions in gene expression (Wheeler et al. 2008). Although most 
cells of the body contain a full set of chromosomes and identical genes, not all 
the gene is involved in gene expression. Only a subset participate in the 
transcription of information from the DNA into messenger RNA (mRNA) 
molecules and translation of mRNA into proteins that perform most of the 
critical functions of cells (Zhou 2010). The amounts of mRNA produced by a 
cell have been used in gene expression studies to evaluate genomic stability 
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and chromosomal aberration by observing which genes are up or down 
regulated as a response to environmental toxicant (Kundu et al. 2011;Moore et 
al. 1997;Udensi et al. 2011a;Zhang et al. 2007;Zhao et al. 1997). High doses 
of arsenic are clastogenic, while low doses are aneugenic and induce sister 
chromatid exchanges in a variety of mammalian cells in vitro (Klein et al. 
2007;Vainio et al. 1981).  ATO has genotoxic effect on human colon cancer 
cells (Stevens et al. 2010) and in keratinocytes (Graham-Evans et al. 2004). 
Arsenic affects cell cycle check points proteins and its inhibition of DNA repairs 
and DNA damage by the production of hydroxyl radicals (H2O2) (Flora 
2011;Shi et al. 2004) and aberrant cytokeratin (CK) expression are consistent 
with skin carcinogenesis process (Sun et al. 2009). 
 
2.3.3 Aberrations in gene expression  
Arsenic causes alterations of gene expression in cultured human keratinocytes 
(Rea et al. 2003). High-throughput gene expression technologies such as 
microarrays have been employed to investigate multiple mechanisms based 
on alterations in expression of target genes. DNA microarrays typically consist 
of thousands of immobilized DNA sequences present on a miniaturized 
surface (Li et al. 1989). Microarrays have been used to propose a mechanism 
of arsenic toxicity/carcinogenicity in skin (Argos et al. 2006), kidney (Sasaki et 
al. 2007), bone marrow (myeloma) (Wang et al. 2006a), peripheral 
lymphocytes (Argos et al. 2006)], neural tube (Wlodarczyk et al. 2006)], liver 
(Liu et al. 2006) and urogenital cells (Su et al. 2006). Other researchers have 
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used microarrays to investigate the effects of arsenic on keratinocytes (Bae et 
al. 2002;Hamadeh et al. 2002).  
 
2.3.4 Cellular immune dysfunction 
Arsenic exposure induces dysfunction of the cellular immune system by 
targeting the CD4+ cells with concomitant reduction in CD4+ cells in epidermal 
keratinocytes which may trigger arsenic induced skin cancer (Kapahi et al. 
2000;Yu et al. 2006).  
 
2.3.5 Distortion of protein structure 
Sulphur is involved in disulphide bonds formation in proteins especially and is 
involved in maintaining stability of protein conformations (Chuang et al. 2003). 
These covalent bonds are the main cross-links present in proteins that are 
involved in folding and stabilizing their three-dimensional (3D) scaffold 
(Kadokura et al. 2003;Wedemeyer et al. 2000). Interaction between arsenic 
and thiol groups disrupts protein conformations (Isokpehi et al. 2010;Snow 
1992). Targets proteins that have high cysteine content and accessible thiol 
groups (Snow 1992) and bind to vicinal cysteines (Isokpehi et al. 2010) and 
such interaction may lead to disruption of the covalent bond and protein 
structure. Arsenite interferes with sulfhydryl group of amino acids and disturb 
protein structure (Chowdhury et al. 2010)(reference). Also, arsenate, which is 
a phosphate analogue, can substitute for phosphate, thus affecting its uptake 
and the cellular processes that involve phosphate including ATP and DNA 
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synthesis (Catarecha et al. 2007;Chavan et al. 2011;Gregus et al. 
2009;Sherwood et al. 2011). 
 
2.3.6 Cell proliferation induction 
The mechanisms by which arsenic enhances cell proliferation have been 
extensively investigated. The mechanisms include induction of over 
expression of growth factors in human keratinocytes (Bailey et al. 
2010;Germolec et al. 1996;Vega et al. 2001), induction of cyclin A with 
increase in S phase population of cells in cell cycle (Chowdhury et al. 2010), 
cyclin-dependent kinase 4 (CDK4), transcription factor 1 (E2F1), granulocyte 
macrophage-colony stimulating factor (GM-CSF), and transforming growth 
factor-alpha (TGF alpha) (Bi et al. 2010;Chowdhury et al. 2010;Germolec et al. 
1996;Vega et al. 2001). Low concentrations (0.5 to 1 µg/ml) of ATO stimulate 
keratinocyte proliferation whereas higher concentrations (> 1 µg/ml) induce cell 
death by activating caspase-3 and cell cycle arrest at the G2-M phase (Bi et al. 
2010;Evens et al. 2004;Graham-Evans et al. 2004).  
 
2.3.7 Epigenetic dysregulation 
An epigenetic trait is an inherited phenotype that results from changes in a 
chromosome without alterations in the DNA sequence (Feinberg et al. 2004). 
Gene expression is regulated by both genetic and epigenetic mechanisms, 
which must be put into perspective in toxicogenomics as well as cell-
transforming ability of arsenic and other toxicants capable of causing 
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aberrations in gene expression and cancer (Arita et al. 2009). Epigenetic 
processes play an important role in gene expression and its dysregulation 
could lead to arsenic-induced changes in gene expression and cancer in both 
people exposed to arsenic directly and those who may inherit the dysregulated 
genes (Drobna et al. 2009;Hei et al. 2004;Jensen et al. 2008;Ren et al. 2011). 
The three major epigenetic mechanisms reported in arsenic toxicity and 
carcinogenicity are; DNA methylation (Ren et al. 2011;Styblo et al. 2002;Zhao 
et al. 1997), histone modification (acetylation, methylation, and 
phosphorylation) (Barr et al. 2009;Jensen et al. 2008;Rahman et al. 2004), and 
microRNA (miRNA) expression (Ghaffari et al. 2012). Hypomethylation of DNA 
may cause overexpression of oncogenic genes (Andrew et al. 2003;Banerjee 
et al. 2007) and decrease in DNA repair, stress defence mechanisms and 
apoptosis (Ahsan et al. 2003;Andrew et al. 2003;Banerjee et al. 
2007;Hamadeh et al. 2002). 
 
2.3.8 Co-carcinogenicity 
Arsenic has also been considered as a weak mutagen and may not initiate but 
potentiate the mutagenicity, cytotoxicity, and clastogenicity of other 
carcinogens such as UV radiation, X-ray and other heavy metals by acting as 
a tumour promoter, or co-carcinogen in skin cancer development. According to 
Yu, et al, 2006, Arsenic and UVB stimulated caspase pathways; caspase-9 
and caspase-8 signalling respectively which induced apoptosis in 
keratinocytes (Rossman et al. 2004;Yu et al. 2006). Also, some studies have 
explored a possible interaction between arsenic exposure and smoking in the 
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causation of cancers of the lung, bladder and skin (Bates et al. 1995;Ferreccio 
et al. 2000;Knobeloch et al. 2006). 
 
2.3.9 Signal transduction interference 
Cell signalling process is a very crucial communication system between cells 
or within a cell in which a change in the activity of the cell is sent as a signal 
that may trigger a cascade of reaction for the body to respond accordingly. 
Cell signal transduction regulates cellular processes such as transcription and 
cell metabolism, and this is reportedly altered under arsenic exposure (Huang 
et al. 2004). The degree of perturbation of the signalling pathways may 
depend on the oxidation state of the arsenic species and cell characteristics 
(Porter et al. 1999;Shen et al. 1975). The role of altered signal transduction 
and cell cycling under arsenic insult has been reviewed extensively (Hughes 
2002;Hughes 2006;Kitchin 2001).  Some of the notable cells signal pathways 
perturbed by arsenic include; activation of mitogen activated protein kinase 
pathway, c-Jun N-terminal kinases (JNK) phosphatase and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) dysfunction 
(Chowdhury et al. 2010;Huang et al. 2004;Kapahi et al. 2000). NF-κB 
dysfunction occurs when arsenic blocks inflammatory signal transduction by 
inhibiting inhibitor of nuclear factor kappa-B kinase (IKK) required to activate 
proinflammatory transcription factor NF-κB (Kapahi et al. 2000). Any process 
that potentiates the activities of NF-κB encourages carcinogenesis since this 
transcription factor promotes proliferation and angiogenesis. Arsenite species 
despite their toxigenic properties also induce translocation of protein kinase C 
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(PKC) isoforms (PKCepsilon, PKCdelta, and PKCalpha) from cytosol to 
membranes where these enzymes interact with MAP kinase (Erks, JNKs, and 
p38 kinases) pathways in a way that may alleviate arsenic toxicity (Chen et al. 
2000).  
 
2.3.10  Reactive oxygen species induction 
Oxidative stress may be described as the imbalance between the production 
of cellular oxidant species and the capability of the cells to produce 
antioxidants (Mates et al. 2008). Arsenic induces skin carcinogenesis by 
disturbing the pro/antioxidant balance namely induction of oxidative stress/ 
reactive oxygen species (ROS), increased transcript levels of keratinocyte 
growth factors, and modulation of MAPK (p38, Erk), Akt and NF-κB pathways 
in exposed cells and permanently activated NF-κB triggers oncogenic effects 
(Kitchin et al. 2010). At the cellular level, exposure to ATO can cause 
morphologic alterations in mitochondrial integrity that leads to inactivation of 
mitochondrial enzymes and loss of mitochondrial membrane potential 
(Pourahmad et al. 2005). Arsenite may act as a bypass for electrons from the 
respiratory chain, that facilitate the formation of superoxide anion radicals and 
generation of ROS (H2O2, O2, ROO, OH, and NO,) (Nesnow et al. 
2002;Pourahmad et al. 2005;Raghu et al. 2009;Shi et al. 2004). Arsenite 
induces a reduction in activity of an important cellular antioxidant, glutathione 
(gamma-glutamylcysteinylglycine, GSH) (Peng et al. 2010). Also, oxygen is 
reduced directly to H2O2 triggering formation of arsenic peroxyl radicals which 
are mediators of DNA damage (Shi et al. 2004;Yamanaka et al. 1990), mitosis 
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disrupters and apoptosis promoters (Kitchin 2001;States et al. 2002). Inorganic 
arsenate stimulates a rapid burst of oxidative stress in mammalian cells as a 
result of the repetitive reduction of pentavalent to trivalent arsenic followed by 
the oxidative methylation of trivalent arsenic (Aposhian 1997). Reactive 
oxygen species, particularly hydroxyl radicals, play an important causal role in 
the genotoxicity of arsenical compounds in mammalian cells (Kitchin et al. 
2010;Liu et al. 2001). A concomitant occurrence of oxidative stress in cells and 
tissues result in increased carcinogenic risk in arsenic-exposed persons. 
Another important trigger of ROS productions is tumour necrosis factor (TNF). 
TNF signalling also involves ROS-dependent modulation of histone 
acetyltransferases (HAT) and deacetylases (HDAC) that causes inflammatory 
gene expression (Rahman et al. 2004). Although ROS trigger signals that 
enhance cell proliferation such as activation of transcription factor AP-1 and 
nuclear factor NF-κB, (Hu et al. 2002;Li et al. 2002), it also has the capacity to 
induce apoptosis through prolonged activation of JNK/AP-1, and SAPK/JNK 
signalling. SAPK/JNK signalling activates AP-1 that stimulates apoptosis 
(Yazdanpanah et al. 2009). AP-1 activity could be very important in explaining 
the discrepancy observed between the proliferative effect of low dose arsenic 
and the pro-inflammatory high dose. ROS can also activate apoptosis signal-
regulating kinase 1 (ASK1), which causes mitochondrial cytochrome c release 
and activation of effector caspases (Matsukawa et al. 2004). The down-stream 
effects of ROS signalling depend on both cell-type and cellular condition. The 
implications for carcinogenesis are therefore variable as well. The detection of 
Anti-8-Hydroxyguanosine (8-OHdG) in urine is suggested as a reliable 
biomarker for oxidative stress (De Vizcaya-Ruiz et al. 2009). 
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2.3.11  Perturbation of Biological Pathways 
Normal cellular activities are altered in different disease conditions (Roden et 
al. 2006). Insights into biological networks perturbed by arsenic exposure 
could help to discover the mechanism of action in arsenic-induced skin cancer. 
A variety of bioinformatics software is now available to reconstruct molecular 
interactions (Chautard et al. 2011;Croft et al. 2011;Stark et al. 2006;Tarcea et 
al. 2009;Turner et al. 2010). 
 
2.4 Biotransformation of arsenic by human microbiome 
2.4.1 Gut Microbiome 
The Human Microbiome Project (HMP) has brought a new perspective on the 
role of human microbial habitats in maintaining normal physiology and 
predisposition to disease (Betts 2011;Turnbaugh et al. 2007). Microbiome is 
the totality of all the microbial flora of humans including bacteria, archaea, 
eukaryotes, and viruses (Turnbaugh et al. 2007). The information on the 
relationship between gut microbiota and cancer is evolving and prompting new 
ways of thinking about cancer prevention. However, toxicologists have linked 
some human cancer to microorganisms. Microorganisms are capable of 
initiating and sustaining chronic inflammation such as Helicobacter pylori, 
enterotoxigenic Bacteroides fragilis (ETBF), Hepatitis B&C, Epstein Barr virus, 
Human papillomavirus (HPV) (Hope et al. 2005). Helicobacter pylori is linked 
with Gastric MALT (mucosa-associated lymphoid tissue) lymphoma, and 
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intestinal cancer (Compare et al. 2011;Hope et al. 2005;Liu et al. 2011) with 
increased cancer risk in allele 2 of the interleukin-1 receptor antagonist gene 
(IL1RN2) genes carriers (Persson et al. 2011). Also associated with colon 
cancer is enterotoxigenic Bacteroides fragilis (ETBF) which secretes B. fragilis 
toxin (BFT) that causes persistent human inflammatory diarrhoea with high 
probability of progressing to colon tumour formation, and gastric cancer 
(Persson et al. 2011). BTF like other carcinogens activate oncogenic pathways 
such as activation of NF-κB, an epithelial tumourigenesis promoter and 
cleavage of E-cadherin, and activation of the β-catenin/Wnt pathway, seen in 
almost all colon cancers (Wu et al. 2009). Chronic hepatitis (Hepatitis B virus 
or Hepatitis C virus) is the major cause of primary liver cancer, which is the 
third leading cause of cancer deaths globally and the ninth leading cause of 
cancer deaths in the United States (El-Serag et al. 2007;Mitchell et al. 
2011;Momin et al. 2011;Wang et al. 2011). Cancer results when 
physiologically responsive cells are transformed into autonomously replicating 
tumours with the ability to invade adjacent tissues and spread widely and 
host/microbiome interaction may yield effects that can either enhance or 
suppress tumourigenesis (Kong 2011). 
A better understanding of the microbial components of the human genetic and 
metabolic sphere has revealed that metabolic processes initially attributed to 
human metabolism are currently observed as microbiome metabolic 
processes. For example, arsenic methylation and reduction under anaerobic 
conditions of the less toxic arsenate to the more toxic arsenite (Styblo et al. 
2002). Interest in the implication of the action of microbes on arsenic has risen 
based on the observation that some microbes in the human gut can 
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metabolise, transform, and speciate arsenic (Alava et al. 2012). Since different 
arsenic species vary widely in their toxicity, improved knowledge on the 
process of pre-systemic arsenic transformation within the body would be a 
boost to deciphering microbiome role in arsenic metabolism. In this regards, 
Van deWiele and co-researchers in 2010, have made some progress. They 
analysed how the human intestinal bacteria metabolize inorganic arsenic from 
contaminated soils. Van deWiele’s team’s demonstrated that bacteria 
metabolized and transformed inorganic arsenic to methylated arsenicals and 
thioarsenicals including monomethylmonothioarsonic acid which is the first 
known metabolically derived thioarsenical (Van de Wiele et al. 2010). This is 
novel because thioarsenicals are not part of the conventional scheme of 
arsenic methylation which results in the production of methylated 
oxyarsenicals (Van de Wiele et al. 2010). The conventional enzymatic 
methylation of trivalent arsenicals (Styblo et al. 2002) is catalysed by AsIII-
methyltransferases which use S-adenosylmethionine (AdoMet) as the methyl 
group donor  (Aposhian et al. 2000;Lin et al. 2002;Zakharyan et al. 1995) and 
yield methylated oxyarsenicals but not thioarsenical. The metabolism of 
ingested arsenate to oxy-and thio-arsenicals before absorption across the 
gastrointestinal barrier could affect bioavailability, systemic distribution, and 
increased toxicity (Pinyayev et al. 2011;Styblo et al. 2002;Thomas et al. 2004). 
It is not clear if the liver enzymatic conversion is a detoxification process 
because methylation of inorganic arsenic activates it to more reactive, toxic 
and carcinogenic forms (Lin et al. 1999) whereas microbial methylation has 
been shown to detoxify arsenic with trimethylarsine as the end product (Cullen 
et al. 1984;Qin et al. 2006).  Comparing the human intestinal flora and human 
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enzymatic metabolism of arsenic, the indigenous microbial flora inhabiting an 
individual metabolizes pre-systemic arsenic to species that are less 
carcinogenic while the human enzymatic arsenic metabolism produces tumour 
enhancing species. Nevertheless, it is still debatable if the products of bacterial 
methylation of arsenic are as carcinogenic as those of human enzymatic 
processes, (Styblo et al. 2002).   Thus, the role of human microbiomes in 
arsenic metabolism and toxicity regulation cannot be overlooked anymore as 
the impact of intestinal bacteria may equal or exceed that of genetic 
polymorphisms that regulate metal transformations within the body (Betts 
2011).  
Aside molecular analysis of arsenic metabolic pathway in the gut microbiome, 
a perspective of the skin microbiome is necessary since arsenic accumulates 
in the skin. Consequently, the evidence of chronic arsenic exposure is 
manifested on the skin. The Human Microbiome Project (Fierer et al. 2008), 
has revealed that each body part has its own unique microbiome which starts 
to populate at birth with several transitions during early life development and 
remain relatively constant until about age 65 (Claesson et al. 
2011;Dominguez-Bello et al. 2010).  
 
2.4.2 Skin Microbiome and Arsenic Metabolism 
The skin is the human body's largest organ, and it acts as the interface 
between the human body and its external environment, preventing loss of 
moisture and entry of pathogenic organisms or toxic substances (Segre 
2006).  The skin is home to many different types of microorganisms. The type 
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and location of organisms found on the skin are influenced by topographical 
location, endogenous host factors and exogenous environmental factors and 
the bacterial density may be as high as 107 cells per square centimetre 
(Fredricks 2001;Grice et al. 2011). Interpersonal variation and intrapersonal 
variation in bacterial community have been observed in human populations. 
The inter-individual differences among human microbiomes may make a 
significant difference in the toxicity of metals (Grice et al. 2008). The skin 
microbial flora consists of both pathogenic and harmless organisms that may 
even be beneficial to their host (Grice et al. 2011). Microbial diversity studies 
show that only less than 1% bacteria of total bacterial diversity can be 
cultured using standard culturing techniques and the remaining 99% microbial 
pool is represented by vast diversity of uncultured bacteria (Amann et al. 
1995). The uncultured bacteria are studied using metagenomic techniques 
which is a culture independent strategy to explore the untapped gene pool of 
uncultured bacteria that may possess novel physiological pathways (Chauhan 
et al. 2009).  The metagenomic techniques include DNA sequencing and 
other genome-based technologies such as NextGen sequencing, 
pyrosequencing (Claesson et al. 2011;Dominguez-Bello et al. 2010), rRNA 
genes (16S rDNA) PCR-based sequencing (Gao et al. 2008;Grice et al. 
2009), TaqMan probes (designed to increase the specificity of qRT-PCR 
assays) (Gao et al. 2010), microRNA (miRNA) (Ahmed et al. 2011;Griffiths-
Jones 2004;Pogribny et al. 2007). Epigenetic techniques have enabled 
studies of fastidious human microbes which were previously difficult to isolate 
and characterize. Such sequence-based approaches are more sensitive than 
traditional cultivation techniques (Gao et al. 2007), and are currently used in 
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identifying the diversity and variability of skin microbiome. The recent 
advances in human microbiome research signals a new horizon for 
translational research in human diseases because the new  knowledge 
gained on the role of microbiome in human skin disorders could be used to 
develop novel pro-microbial and antimicrobial therapeutic approaches for their 
treatment and prevention (Grice et al. 2011;Kong 2011).  The normal human 
superficial bacterial biota is highly diverse with 182 species-level operational 
taxonomic units (SLOTUs) belonging to eight phyla observed after examining 
the skin biota from the superficial volar left and right forearms in six healthy 
subjects using broad-range small subunit rRNA genes (Gao et al. 2007). 
Microbial colonization on the skin adds to the skin's defence against 
potentially pathogenic organisms (Roth et al. 1988). Exposure to 
environmental toxicants such as arsenic may have the potential to alter the 
skin microbiome selectively and may underlie the incidence of human skin 
disorders as seen in arsenic water contamination in endemic communities.  
 
2.4.3 Bacteria arsenic metabolism 
Bacteria metabolize arsenic to evade its toxic effects. The ars genes 
possessed by most organisms help to develop arsenic resistance. As shown 
in Table 3, the ars genes are organized in operons, such as arsRBC, 
arsRABC, and arsRDABC, but in some cases the ars genes appear singly 
(Butcher et al. 2000;Butcher et al. 2002;Diorio et al. 1995;Sato et al. 1998). 
The ars operon is conserved mostly in Gram-negative bacteria and has a 
functional role in arsenic detoxification (Diorio et al. 1995). The ars system is 
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an arsenic responsive mechanism observed in most living organisms and 
further exploration of the activities may lead to discovery biomarkers of 
arsenic insult. The ars genes perform different functions in arsenic 
metabolism; the Transcriptional repressor (arsR) encodes an As(III)-
responsive transcriptional repressor, (Wu et al. 1991) that binds to target 
promoters and controls the expression of other ars genes (Rosenstein et al. 
1994;Wang et al. 2009). Anion-transporting ATPase (arsA) as the name 
implies functions as an ATPase. Arsenical pump membrane protein (arsB) is 
a membrane efflux transporter. ArsA and ArsB form an oxyanion-translocating 
complex  (Rosen 2002). And sometimes arsB function without arsA in arsenic 
extrusion (Dey et al. 1995).  Arsenate reductase and related proteins are 
encoded by glutaredoxin family (arsC) and it converts arsenate to arsenite. 
Also, AqpS which encodes water-transport channel participates in a arsC-
catalysed reduction to induce resistance (Yang et al. 2005). AqpS is also 
known to transport glycerol in plants due to their lack of aquaglyceroporins 
(Zardoya R 2002). Arsenical resistance operon trans-acting repressor (arsD) 
is an arsenic metallochaperone which increases the rate of arsenic extrusion 
by transferring As(III) to ArsA (Lin et al. 2006;Wu et al. 1993). ArsD is a 
homodimer and each of its subunit has three vicinal cysteine pairs, Cys12-
Cys13, Cys112-Cys113 and Cys119-Cys120 (Lin et al. 2007). These vicinal 
cysteines are probably the binding sites of the proteins to arsenic. Another 
member of the ars gene operon, arylsulfatase family, member H (arsH) 
encodes an NADPH-flavin mononucleotide oxidoreductase which is involved 
in arsenic resistance in Yersinia enterocolitica and Sinorhizobium meliloti 
(Neyt et al. 1997). Another arsenic resistance gene arsM encodes an arsenite 
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S-adenosylmethionine methyltransferase (Wang et al. 2009) which plays a 
role in arsenic detoxification in bacteria. arsM stimulates arsenite [As(III)] 
resistance by catalysing the formation of a number of methylated 
intermediates from As(III), and production of volatile trimethylarsine (Qin et al. 
2006). A putative membrane permease (ArsP) is also a member of the ars 
gene operon. Both arsD and arsA play crucial role in the binding and 
extrusion of the reduced arsenite from the bacteria and into the host 
environment. The ArsD metallochaperone delivers trivalent metalloids, As(III), 
to the ArsA ATPase, the catalytic subunit of the ArsAB As(III) efflux pump. 
Transfer of As(III) increases the affinity of ArsA for As(III), allowing resistance 
to environmental arsenic concentrations. Two different transport mechanisms 
are involved in the uptake of the two different arsenic oxidation states; (i.) 
phosphate transporters which facilitate the uptake of As(V) in the form of 
arsenate and (ii.) the aquaglyceroporins which transport As(III) in the form of 
arsenite. Other mechanisms of bacterial arsenic resistance include; the 
reduction of As(V) to As(III) by arsenate reductases, and extrusion or 
sequestration of As(III). The extrusion is mediated by efflux transporters, 
reduction of arsenate [As(V)] to arsenite [As(III)], which is subsequently 
extruded by efflux transporters and  methylation of As(III) by S-
adenosylmethionine methyltransferase (Qin et al. 2006;Rosen 2002;Yuan et 
al. 2008).  
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Table 3: Arsenic Responsive Genes in Bacteria 
Organism Operon Gene Function References - 
PubMed 
Identifiers 
(PMID) * 
Campylobacter jejuni Ars operon Putative membrane 
permease (ArsP) 
Resistance to 
arsenite and 
arsenate 
PMID: 9537360, 
PMID: 19502436 
Campylobacter jejuni, 
Staphylococcus 
xylosus (pSX267), 
Bacillus subtilis skin 
element, 
Staphylococcus and 
Escherichia coli 
 Transcriptional repressor 
(ArsR) 
 PMID: 8121414, 
PMID: 1838573, 
PMID: 9537360, 
PMID: 19502436 
Campylobacter jejuni , 
Bacillus subtilis skin 
element, 
Staphylococcus and 
Escherichia coli 
 Arsenate reductase (ArsC)  PMID: 19502436, 
PMID: 7721697 
Campylobacter jejuni  Efflux protein (Acr3)  PMID: 19502436, 
PMID: 21299644 
  arsA  PMID: 21299644 
Bacillus subtilis skin 
element 
 Carrier protein (ArsB) Arsenic transport PMID: 10354596, 
PMID: 9537360 
Escherichia coli  Anion-translocating ATPase 
(ArsAB) 
 PMID: 10354596, 
PMID: 7814328, 
PMID: 21299644 
Salmonella enterica  arsD, metallochaperone  PMID: 21313837, 
PMID: 21188475, 
PMID: 21299644, 
PMID: 21299644 
Crocosphaera watsonii  arsH  PMID: 19283378, 
PMID: 22046174 
Escherichia coli  AsIII S-adenosylmethionine 
methyltransferase  (arsM) 
 PMID: 18522094 
Bacillus subtilis skin 
element 
 ORF2,  PMID: 9537360 
Saccharomyces 
cerevisiae 
 acr1 Transport PMID: 9374482 
 
Saccharomyces 
cerevisiae 
 acr1 Transport PMID: 9374482 
Saccharomyces 
cerevisiae 
 Acr3p Arsenite extrusion, 
transport 
PMID: 10801893, 
PMID: 10220408, 
PMID: 9374482 
Saccharomyces 
cerevisiae 
 Ycf1p Transport PMID: 10220408 
Achromobacter sp. 
SY8 and 
Pseudomonas sp. 
TS44 
arsenite 
oxidase (aox) 
aoxX-aoxS-aoxR   PMID: 19283378 
Achromobacter sp. 
SY8 and 
Pseudomonas sp. 
TS44 
 aoxA-aoxB-aoxC-aoxD  PMID: 19283378 
** Citation for PubMed can be obtained from http://www.pubmed.gov 
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2.5 Skin Cancer overview 
Skin cancer is the most common of all human cancers. Annual global 
incidence of non-melanoma skin cancers is currently, between 2 and 3 million, 
and about 132,000 for melanoma skin cancers (WHO 2012). More than 1 
million people are diagnosed with skin cancer each year in the United States.  
There has been steady increase in the incidence of both non-melanoma and 
melanoma skin cancers over the past decades. Most skin cancers are benign 
but some are malignant and capable of metastasis. The major types of skin 
cancer are: basal cell carcinoma (BCC) (Zoccali et al. 2011), squamous cell 
carcinoma (SCC) (Kraljik et al. 2011) and melanoma. Basal cell carcinomas 
and squamous cell carcinomas are described as non-melanoma and are more 
common in older people while melanomas are more common in younger 
people. For example, melanoma is the most common cancer in people 25-29 
years of age. Other types of non-melanoma skin cancers are; 
keratoacanthomas, Merkel cell carcinoma, skin lymphoma, Kaposi sarcoma, 
skin adnexal tumours, and sarcomas (ACS 2012;Kramkimel 2013). Most 
common cause of skin cancer is ultraviolet radiation (UVR) exposure, mostly 
from sunlight. Other important causes include; use of tanning booths, 
immunosuppression-impairment of the immune system,  exposure to unusually 
high levels of x-rays, contact with certain chemicals such as arsenic, 
hydrocarbons in tar, oils, and soot. People most prone to skin cancer are those 
with fair skin that freckle, sunburn easily, or become painful in the sun, blond 
or red hair and blue or green eyes, certain genetic disorders that deplete skin 
pigment such as albinism, xeroderma pigmentosum, treated skin cancer, 
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numerous moles, unusual moles, or large moles that were present at birth, and 
those who inherit the genes from their parents.  
 
2.5.1 Basal cell carcinoma (BCC) and Squamous cell carcinoma (SCC) 
Basal cell carcinoma and Squamous cell carcinoma are the frequently 
encountered type of malignant skin cancer and they do not normally spread to 
other tissues but may disfigure the affected area if not treated promptly. The 
BCC affects mostly people over 50 years with children in rare occasions 
(Skellett et al. 2012;Zoccali et al. 2011). Additionally, SCC has a high 
prevalence among the elderly, 70 years and over. This maliganant cancer 
affects the parts of the body exposed to sunlight such as the head, neck and 
backs of the hands with the ratio of the photo exposed area to photo non-
exposed area as 5:1 (Kraljik et al. 2011). Squamous cell cancinoma is initiated 
as a small nest of aberrant cells expands to dominate a tissue and form a 
macroscopic tumour. During early neoplastic progression, pre-invasive lesions 
demonstrate dysplastic foci that are initially surrounded by normal, undisturbed 
tissue (Farber 1996).  
 
2.5.2 Melanoma 
Malignant melanoma accounts for most of the fatalities associated with skin 
cancer as it is aggressive and spreads easily to other organs. Exposure to 
ultra violet radiation (UVR) from the sun is the major cause of melanoma 
worldwide. Iit is more prevalent among White populations than in Black African 
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and Asian populations (Armstrong et al. 1993). This is attributed to the melanin 
content and melanosome dispersion in people of colour compared with light-
coloured skin persons.  The light-coloured skin readily absorbs UV light and 
thus more susceptible to UV damage (Taylor 2002). Although the body most 
often recovers and repairs the damage caused by exposure to UV light, co-
exposure to arsenic may hamper the repair mechanism leading to cancer 
development (Rossman et al. 2004;Taylor 2002). Exposure to UV rays 
increases the risk of developing non-melanoma skin cancer (Wei-Passanese 
et al. 2012). Melanoma begins in melanocyte (cells that make the pigment 
melanin) as moles in the skin and other pigmented tissues including the eye or 
in the intestine (Skellett et al. 2012;Zoccali et al. 2011). About 76,250 new 
cases are estimated to be diagnosed and 9,180 are projected to die of 
melanoma in the United States in 2012. The aetiology of melanoma, the most 
lethal form of skin cancer, is complex, involving both genetic and 
environmental components. MicroRNA (miRNA)-mediated epigenetic 
regulation of tumour suppressor genes and oncogenes has been shown to 
play a central role in melanomagenesis (Bonazzi et al. 2012).  Most skin 
cancers start as a mole which undergoes dysplastic changes to become 
actinic keratosis, a patch of red or brown, scaly, rough skin, a precursor to 
SCC or melanoma. 
 
2.5.3 Skin Cancer Treatment 
Basal cell carcinoma and squamous cell carcinoma are treated by surgical 
removal of the lesion. Malignant melanoma is more complicated and may 
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require different approaches depending on the stage and organs involved. The 
treatment methods include surgery, radiation therapy, and chemotherapy 
(Bajetta et al. 2002;Burusapat et al. 2012). 
 
2.6 Skin Cell Culture System 
The mammalian skin is a complex dynamic organ composed of thin multi-
layered epidermis, a thin layer of basement membrane and a thick underlying 
connective tissue layer dermis containing fibroblasts (Figure 2). The epidermis 
provides physical, chemical ⁄ biochemical (antimicrobial, innate immunity) and 
adaptive immunological barriers. The skin function as a physical barrier lies 
mostly on the stratum corneum which is the outermost layer. But it is 
supported by the nucleated epidermis, especially the cell–cell junctions and 
associated cytoskeletal proteins. The presence of lipids, acids, hydrolytic 
enzymes, antimicrobial peptides and macrophages also assist the skin to 
function as a chemical and antimicrobial and a boost to innate immunity 
(Proksch et al. 2008).  
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Figure 2: Human skin physiological constituents 
From: http://www.ocaesthetics.org/images/pic-dermal-medical-skin-
care-1.jpg (Williams 2012) 
 
The epidermis is continually renewed and replaced throughout life (Singh et al. 
2012). Sustained keratinocyte growth required both intact basement 
membrane and dermal fibroblasts. Different skin cells have been used to study 
the molecular nature of carcinogens and tumour promoters such as arsenic. 
Since there is wide variability between how laboratory animals and human 
metabolize arsenic, several skin constructs to simulate human skin system 
have been developed to enable in vitro experiments. Depending on the 
experimental design, keratinocytes cell model systems have been develop to 
answer different biological questions. Some of the models include (i.) single 
layer cell culture; e.g. Human Keratinocyte (HK), Normal human epidermal 
keratinocytes (NHEK), a spontaneously immortalized human keratinocyte cell 
line  (HaCaT cells), 3T3 fibroblast, (ii.) organotypic keratinocytes culture and 
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(iii.) co-cultures system. Examples of co-culture are; keratinocytes-
melanocytes coculture system, keratinocyte culture with collagen gel, 
keratinocyte coculture with 3T3 fibroblast, a co-culture of human keratinocytes 
and Staphylococcus aureus (Ahn et al. 2010;Ma et al. 2010;Nicolay et al. 
2003;Tandara et al. 2011;Wiegand et al. 2009), collagen/fibroblast (Wu et al. 
1982). Organotypic cultures may help in understanding how the basement 
membrane components and/or dermal fibroblasts direct the assembly and 
organization of structured basement membrane and the concomitant 
normalization of epidermal phenotype (Andriani et al. 2003;Javaherian et al. 
1998;Margulis et al. 2003). A example of organotypic culture system is Merkel 
cells (MCs) containing epidermal sheets embedded in collagen gel. This model 
has been used to estimate the effects of nerve cells on the maintenance of 
MCs within the epidermis. Merkel cells are normally located in the epidermal 
basal layer, in contact with keratinocytes (Nagase et al. 2009). Organotypic 
cultures with HaCaT cells have been developed to investigate cell migration 
and differentiation (Hinitt et al. 2011). Organotypic cultures have a high level of 
tissue normalization with the ability to form a structured, mature basement 
membrane when the construct involves dermal fibroblasts grown on pre-
existing basement membrane components (Andriani et al. 2003;Javaherian et 
al. 1998;Margulis et al. 2003). 
 
2.7 Microarray and PCR Technologies 
A microarray is a tool for analysing gene expression. DNA microarrays are 
basically miniaturized solid surfaces (membrane or glass slides) with 
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immobilized sequences from thousands of different genes stationed in a 
regular pattern at specific spots (Koschmieder et al. 2012). Gene expression 
encompasses all the processes from the transcription of the information 
contained within the DNA, into messenger RNA (mRNA) molecules to the 
translation into the proteins which perform most of the critical functions of cells. 
Although full set of chromosomes and identical genes may be found in every 
cell, not all are turned on or participate in the transcription process. Thus, only 
the subset that is transcribed confers unique properties to each cell type 
(Benson et al. 2008). The amounts of mRNA produced by a cell are studied to 
learn which genes are expressed, and how the cell responds to its changing 
needs (Benson et al. 2008). Although DNA microarrays are excellent tools in 
discovery-based genomic and biomedical research (Edgar et al. 2006;Sun et 
al. 2007), additional verification tests especially RT-PCR are needed to 
confirm that the genes of interest are differentially expressed. This is due to 
the variability that exist in microarray results from laboratory to another, user to 
user, and platform to platform (Larsson et al. 2006). Real-time PCR, also 
referred to as quantitative reverse transcription PCR (RT-qPCR), and 
quantitative PCR (qPCR), is a very powerful and sensitive gene analysis 
technique. It is used for a broad range of applications including quantitative 
gene expression analysis, genotyping, copy number, drug target validation, 
biomarker discovery, pathogen detection, and measuring RNA interference 
(Invitrogen 2012). The difference between Real-time PCR and traditional PCR 
is that Real-time measures PCR amplification as it occurs, thus making it 
possible to determine the starting concentration of nucleic acid. In contrast, the 
traditional PCR, results can only be collected after the reaction is complete, 
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making it impossible to determine the starting concentration of nucleic acid 
(Arya et al. 2005;Invitrogen 2012). 
Real time PCR is able to produce the qualities lacking in microarray such as 
high detection sensitivity, sequence specificity, large dynamic range as well as 
its high precision and reproducible quantitation (Wang et al. 2006b). Thus, RT-
PCR is regarded as the “gold standard” for microarray confirmation (Shippy et 
al. 2004). The basic principles of RT-PCR and its application in molecular 
diagnostics based on high-throughput, automated technology with lower 
turnaround times has been reviewed in detail (Arya et al. 2005). SYBR Green 
and TaqMan (fluorogenic 5’ nuclease chemistry) gene expression assays are 
the two common fluorescent reporter molecule in real-time PCR based 
techniques designed to evaluate microarray experiments. SYBR® Green I, is a 
dye that binds to double-stranded DNA, to detect PCR product as it 
accumulates during PCR cycles (Schneeberger et al. 1995;Xiang et al. 2012) 
while in Taqman a fluorogenic probe is used to monitor accumulation of a 
specific PCR product during PCR cycles (Life Technologies 2012;Wang et al. 
2006b). The amount of fluorescence emitted from the fluorophore increases as 
the quantity of target amplicon increases (Arya et al. 2005;Invitrogen 2012). A 
schematic diagram comparing TaqMan and SYBR Green chemistries is shown 
in Figure 3. 
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Figure 3: Gene expression assay reaction steps comparison of TaqMan 
and SYBR Green chemistries 
Source: Invitrogen Corporation (Invitrogen 2012) 
 
 
2.8 Computational Biology, Bioinformatics tools and data bases 
Computational biology is the development of a technique and the validation 
test of the developed technique. Bioinformatics is the field of science in which 
biology, computer science, and information technology merge to form a single 
discipline (Baxevanis et al. 2005). Bioinformatics is applied in the validation, 
adaptation and usage of the computational biology techniques to numerous 
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real life problems. Bioinformatics tools and techniques have enabled the 
discovery of new biological insights and creation of a global perspective from 
which unifying principles in biology have been discerned. The bedrock of 
Bioinformatics is the creation and advancement of databases, algorithms, 
computational and statistical techniques and theory to solve formal and 
practical problems arising from the management and analysis of biological 
data (Benson et al. 2007). To maintain the database, existing data must be 
updated regularly with new or revised data, and designs and user friendly 
interfaces to grant researchers easy access (Kulikova et al. 2007;Sugawara et 
al. 2007). 
Bioinformatics tools and techniques are currently used to analyse and interpret 
various types of data, including nucleotide and amino acid sequences, protein 
domains, and protein structures (De et al. 2006). Scientists have been able to 
determine how normal cellular activities are altered in different disease 
conditions (Roden et al. 2006). 
Computational biology techniques will be applied in the course of this research 
analyses and interpretation of the high-throughput data that will be generated.  
Tools such as; Michigan Molecular Interactions (MiMI) web tool 
(http://mimi.ncibi.org), (Tarcea et al. 2009), Cytoscape web (Lopes et al. 2010) 
and Dianna web server, (http://clavius.bc.edu/~clotelab/DiANNA/) (Ferre et al. 
2006) have developed algorithms and statistical methods with which to assess 
relationships among members of large data sets, such as methods to locate a 
gene within a sequence, predict protein structure and/or function, and cluster 
protein sequences into families of related sequences.  
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Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Redwood City, CA) is a 
software for determining models of biological pathways and networks that are 
significantly represented in the differentially expressed (both up and down 
regulated) genes. It generates a P-value for each network and canonical 
pathway, which is the likelihood that a given network was identified by chance. 
IPA assigns biological functions to each network by using annotations from 
scientific literature stored in their knowledge base. Fisher exact test is used to 
calculate the P-value for each biological function/disease or pathway being 
assigned by chance.  
 
2.8.1 Comparative Toxicogenomics Database 
Comparative Toxicogenomics Database (CTD http://ctd.mdibl.org/) advances 
understanding of the effects of environmental chemicals on human health. The 
interactions between environmental factors and genes that modulate important 
physiological processes are proposed as the underlying cause of most chronic 
diseases (Olden et al. 2000;Schwartz et al. 2004;Toscano et al. 2005). This 
conclusion is based on the observations that many complex diseases are 
caused by reversible behaviours or avoidable exposures. Additionally, there is 
relatively rare number of diseases attributed to single gene mutations (Olden 
et al. 2000). Many common conditions including asthma, cancer, diabetes, 
hypertension, immune deficiency disorders and Parkinson’s disease have 
been linked to environmental factors. But there is an information gap on the 
molecular mechanisms underlying these correlations (Toscano et al. 2005). 
The CTD is a repository for curated data which describe cross-species 
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chemical–gene/protein interactions and chemical– and gene–disease 
relationships. The molecular mechanisms underlying variable susceptibility 
and environmentally influenced diseases and complex chemical–gene and 
protein interaction networks could be studied using the CTD.  
  
2.9 Visual Analytics 
Visual analytics is an emerging discipline that combines visualization methods 
with data analysis and human-computer interaction (Alako et al. 2006;Hu et al. 
2004;Moll et al. 2005). Visual analytics is increasingly used to analyse 
multidimensional biological datasets of all sizes and presenting them in an 
interactive visual display with one of the purpose to identify patterns (Chabot 
2009;Johnson et al. 2010;Shih et al. 2011;Udensi et al. 2011b). The purpose 
of visualization is to transform the invisible to visible. Visual analytics is 
different from other data analysis methods because it integrates visualization 
with data analysis. The iterative and synergistic process of visualization and 
analysis which is facilitated by computer hardware technology makes it easy 
for the user to interact with the software and gives an opportunity to 
manipulate the data to formulate different hypotheses based on the data 
analysis results (Heer et al. 2006). The visualization approach could allow the 
researchers to make discoveries faster. Visual analytics methods make it easy 
to mine, analyse and assimilate the mounds of complex data generated from 
high throughput screening (HTS) techniques such as flow cytometry, 
genotyping, DNA, RNA, RNAi sequencing, without losing crucial information 
patterns which can easily be lost using traditional statistical techniques (Pui 
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Shan et al. 2006). The Excel-based spread-sheet paradigm does not provide 
the level of human-computer interaction that is necessary to both understand a 
complex data set and inform data mining and machine learning analyses. 
Visualization helps the investigator to become familiarized with their high-
dimensional data in a way that might not be possible with a spreadsheet or 
database. Application of visual analytics tools have evolved over the years. 
Earlier tools such as the protein-protein binding databases DIP (Xenarios et al. 
2001), was used to demonstrate dynamic visualization of interaction networks. 
This allowed users to navigate among links in particular data sets. Recent 
visualization and analysis tools such as Cytoscape (Ideker et al. 2002), 
MintViewer (Zanzoni et al. 2002) and Osprey (Breitkreutz et al. 2003), have 
expanded this concept. They include features for viewing and querying larger 
subsets of the interactome on a more global scale. The tools typically operate 
from the viewpoint of physical associations among proteins, or correlated gene 
expression, and include information that summarizes annotated functions, 
such as Gene Ontology (GO) (Ashburner et al. 2000) groupings, among sub-
networks of linked genes or proteins. VisANT, a protein interaction databases 
is a unique tool to store, in a computer readable form, the protein interaction 
information disseminated in the scientific literature (Hu et al. 2004). There are 
general purpose visual analytics which provide simple, interactive way of 
exploring and interpreting data that have been very useful in the analysis of 
scientific data. These tools were created to process and visualize categorical 
data such as census and survey data, inventory, weather forecast and any 
data that can be summed up in a cross-tabulation. Examples include the 
Tableau Software (Shih et al. 2011;Tableau 2012), Parallel Sets (ParSets) 
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(Kosara 2012), Yurbi (Yurbi 2012). These softwares are used in analysing 
huge business data to deliver quick business intelligence such as using the 
data result to develop business cases that prioritize and reliably quantify the 
impacts of value improvement projects, and to convert data into actionable, 
accessible information to drive decision making (HFMA 2012).  
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Chapter 3 
Research Methodology 
3.1 Materials/Methods  
3.1.1 Chemical and Reagents  
 ATO (dissolved in dilute nitric acid, 1mL = 1mg As, Reference Standard 
Solution, 1000µg/ml +/-1%/Certified, 99.9% purity, Fisher Scientific 
Suwanee, GA) dilutions were prepared using a complete DMEM 
medium as the diluent. 
 Foetal bovine serum (FBS, Hyclone Laboratories Logan, UT), 
 Dulbecco’s modified Eagle’s Medium (DMEM),  
 Phosphate buffered solution (PBS 1x) (ATCC, Manassas VA) and 
Streptomycin/Penicillin antibiotics (Invitrogen, Carlsbad, CA), were 
purchased for culturing the HaCaT cell line.  
 The MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide] 
reagent was obtained from ATCC (Manassas VA) 
 Collagen-IV from Sigma Chemical Company (St. Louis, MO) (Lot no 
108K0503) 
 Ambion Message Amp aRNA kit (Cat. No. 1753) or Ambion amino allyl 
cDNA kit (Cat. No. 1705) 
 NanoDrop ND-1000 for optical density measurement  
 The reactive amino group of 5-(3-aminoallyl)-UTP/5-(3-aminoallyl)-
dUTP was used to conjugate the purified aRNA/cDNA with the NHS-
CyDye 
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3.2  Experimental Design 
This research has two components: 
(i) Wet laboratory experiments: This include the following 
experiment 
Cell culture 
Evaluation of chronic toxicity of ATO to keratinocytes 
Genotoxicity experiment 
RNA extraction and gene expression studies 
 
(ii) Bioinformatics analyses of the high throughput data generated 
from the wet laboratory experiments 
 
3.3 Wet laboratory experiments 
3.3.1  Cell Culture Procedure 
The HaCaT keratinocytes used for this research were provided by Dr Van 
Wilson (Microbial & Molecular Pathogenesis, College of Medicine, Texas A&M 
Health Science Centre, College Station, Texas, USA).  Approximately 1.5 ×105 
HaCaT cells were cultured in 10 ml of complete DMEM in T-25 culture flasks 
and incubated in a humidified atmosphere with 5% CO2 at 37 ºC. The culture 
medium was replaced every 96 hours. The cells were split after growing to 
90% confluence by aspirating the culture medium and washing the cell 
monolayer three times with sterile phosphate buffered saline (PBS). The cell 
monolayer was treated with 2 mL 0.25% trypsin-EDTA per plate and incubated 
briefly at 37 ºC. The cells were then viewed under the microscope to ensure 
that cells were completely detached and were re-suspended in a complete 
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DMEM medium. An aliquot of the HaCaT cell suspension was stained with 4% 
trypan blue for 1 to 2 minutes and counted with a haemocytometer. The cells 
used for chronic exposure were considered chronic after undergoing 10 
passages (cells trypsinised at 90% confluence, Figure 4, and sub-cultured in 
another cultured flask). In this research investigation, acute cells are defined 
as the cells that were exposed to ATO for the first time while chronic cells are 
cells that have been exposed continuously up to 10 passages with a very low 
dose 0.5 µg/ml of ATO.   
 
Figure 4: 100% Confluent HaCaT cell culture 
 
 
3.3.1.1 Protocol for Splitting of Cells 
 The media (DMEM), trypsin-EDTA and PBS were warmed up in 37o 
C water bath 
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 Inside the hood (Using sterile environment), 10 ml of media were 
added to new T-25 culture flasks  
 Old media were aspirated from cell culture flasks and washed twice 
with 10 ml sterile PBS 
 PBS was aspirated and  2ml Trypsin-EDTA solution was added to a 
confluent culture flask as shown in Figure 4, and the flask tilted to 
mix 
 The flask was incubated at 37 C for 2 minutes or until cells were 
observed to detach from the plate  
 5 mL of media was added to each plate to stop trypsinisation 
reaction and was transferred to sterile 15ml centrifuge tube. 
 The cell suspension was centrifuged at 800 rpm for 5 min at room 
temperature 
 The supernatant was aspirated, and 4 ml of fresh media added to 
cell pellet 
 The cells were mixed by pipetting up and down gently for several 
times 
 Cell count was performed using haemocytometer  
 The cells were either used for plating or stored frozen  
 One confluent T-25 flask was used to plate four T-25 flask i.e. 
remove 1ml of cell suspension from the trypsinised cell and transfer 
to a new T-25 flask with fresh media  
 The media (DMEM), trypsin-EDTA bottle caps were tightly closed 
and returned to 4o C. 
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3.3.1.2 Cell Count Calculation 
 Four large squares (with 16 smaller squares) of the 
haemocytometer were   counted 
 Total Cells Count/ml = the average count x the dilution factor x 104  
 Total Cells Count/ml = count in 4 large squares/4 x total volume 
(4ml) x 104 
 Assuming the count from four squares= 184 
 Total Cells Count/ml = 184/4 x 4 x 104  = 184 x 104 =18.4 x 105/ml 
 
3.3.1.3  Determination of Concentration of Cells to Plate  
Concentration of Cells to Plate = Cell concentration required / total cell 
count/ml x volume required 
Concentration required = 1.5 x 105/ml 
Volume required = 10ml 
Total Cell Count = 18.4 x 105/ml 
1.5 x 105 / 18.4 x 105 x 10ml = 0.8ml 
Therefore 0.8ml of well mixed cell suspension will be transferred to a 
fresh flask containing 10 ml medium. 
 
3.3.1.4 Cryopreservation of HaCaT Cells  
The HaCaT cells at each passage were cryopreserved to avoid loss by 
contamination and to avoid genetic drift. The cells were checked for 
contamination prior to cryopreservation. A seed lot system was used in which 
a portion of the lot at each passage is designated as seed material and is set 
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aside from the working stocks. It is stored different to avoid being used until 
the first working stock lot has been depleted (Hay 1988). The seed lot serves 
as a source for subsequent working stock. 
The Cryopreservation media used consist of 10% DMSO 
(dimethylsulfoxide) 
 Under the hood (sterile environment), a 0.22 µl pore filter was 
attached to the tip of a 10 ml syringe with the plunger pulled out 
 9 ml of foetal bovine serum (FBS) was transferred into the barrel 
of the 10 ml syringe 
 The plunger was put back and pushed to filter the FBS into a 
sterile 15 ml centrifuge tube 
 1 ml of DMSO was added to the filtered FBS 
 The tube was labelled “Freezing Medium” and was placed at 4 
°C  
 1x105 cells/ml was added to 1ml freezing media in a 1.5 ml 
cryovial 
 The cryovial was placed in Thermo Scientific Nalgene Mr Frosty 
freezing container overnight at -80 °C to achieve a uniform 
cooling rate close to -1 °C per minute. 
 A vial of the frozen cell was tested to determine if the cells 
survived the freezing procedure. The cells were thawed and 
tested for viability and ability to establish a cell population after 
been frozen for 48 hours 
 The vials were transferred to liquid nitrogen freezer at -150 °C 
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3.3.2 Cytotoxicity Assay (MTT Assay) 
Cytotoxicity assay is applied to evaluate chronic and acute toxicity of ATO to 
skin keratinocytes. MTT Cell Proliferation Assay Kit is a basic method used to 
measure cell viability and proliferation in response to external stimuli such as 
drugs and cytotoxic agents. It can also conversely determine the reduction in 
cell viability due to metabolic events such as apoptosis or necrosis. The MTT 
assay was developed by Mossman (Mosmann 1983) and it is an indirect 
method using standard microplate absorbance readers. Its fluorescent or 
chromogenic indicators provide the most rapid and large scale assays. MTT 
assay involves the reduction of the water soluble yellow tetrazolium MTT (3-(4, 
5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) to an insoluble 
intracellular purple formazan and reducing equivalents such as NADH and 
NADPH by metabolically active cells and in part by the action of 
dehydrogenase enzymes. The formazan is then solubilized, and the 
concentration quantified by spectrophotometric means at optical density 570 
nm. The result is a sensitive assay with a low background absorbance values 
in the absence of cells. Also, an excellent linear relationship between cell 
number (up to approximately 106 cells per well) and signal produced is 
established, which allows an accurate quantification of changes in the rate of 
cell proliferation or cell death. 
Two MTT cytotoxicity assays were performed: 
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1. To determine the LD10/LD 50 and estimate the minimal cytotoxic 
concentration that would be used to establish a chronic cell 
exposure condition 
2. To determine dose response and cytotoxic patterns in chronically 
exposed and acutely exposed skin keratinocytes to ATO 
 
3.3.3 MTT Test 1 
Dose response relationship was determined by measuring the survival rate (% 
viability) of cells after treatment with ATO using MTT (tetrazolium salts) assay 
as follows; about 3×104 cells suspended in 200 µl of medium were inoculated 
in each well of a flat-bottom 96-well culture plate. There were nine 
experimental groups: negative control, blank control (no cells, no arsenic), and 
seven arsenic treatment groups with final concentrations of ATO of: 0.0, 1.0, 
5.0, 10.0, 15.0, 20.0 and 25.0 µg/ml as shown in Table 4 and Figure 5 . Each 
of the group was exposed to ATO for 48 hours. The cells were treated with 20 
µl MTT cell proliferation assay kit (lot no: 9426FS) and incubated for 4 hours. 
100 µl of detergent solution was added and incubated in the dark for 2 hours. 
The absorbance was measured at wavelength 570nm in a microplate reader 
(Fluoroskan II microplate reader Helsinki, Finland). Acute cytotoxicity 
experimental results were used to determine tolerated dose (LD10) in all the 
cell lines for chronic assays as used by Trouba et.al, (Trouba et al. 1999). 
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Table 4: Concentration of ATO used for LD50 determination on HaCaT 
cells 
Concentration 100 µg/ml Stock 
ATO 
Media (µl) Final Volume 
(µl) 
25 500 1500 2000 
20 400 1600 2000 
15 300 1700 2000 
10 200 1800 2000 
5 100 1900 2000 
1 20 1980 2000 
0 0 2000 2000 
 
 
 
Figure 5: Culture media and arsenic dilutions used for MTT Assay.  
A: phosphate buffered saline (PBS), B: culture medium (DMEM), C: 
different concentrations of ATO diluted with DMEM, 96 well plates set up 
for MTT Assay 
 
3.3.4. Collagen Coating 
Collagen IV is the major constituent of basement membrane and is used in 
coating cell culture surfaces to establish long-term cultures because it 
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provides a good physiological coating for the culture of many cell types. 
Collagen coating was performed using Kleinman’s method (Kleinman 2001).  
Protocol: 
 Stock solution was thawed slowly on ice 
 Culture plates and pipette tips were pre-chilled on ice for 20 
minutes 
 Collagen IV stock solution was diluted with pre-chilled PBS 1:30 
Concentration in 1ml stock solution of collagen IV = 0.3 mg ≡ 
300 µg/ml 
Required concentration = 30 µg/ml 
Want/Have = 30/300 = 0.1 
Therefore 0.1 ml collagen IV + 0.9 ml PBS = 30 µg/ml 
 75 µl of Collagen IV (30 µg/ml) was transferred to pre-chilled 
wells of 96 well tissue culture plates  
 The solution was evenly spread to completely cover the flat-
bottom of the wells. The plates were incubated at 37°C for 2 
hours and washed 3 times with sterile phosphate buffered 
saline.  
 
3.3.5 MTT Assay 2 
Eight different 96 well plates were used for the different time-points; 4 different 
96 well plates labelled day 2+AS, day 5+AS, day 8+AS and day 14+AS for the 
chronic cells treatment group and additional 4 different 96 well plates labelled 
day 2-AS, day 5-AS, day 8-AS and day 14 -AS for the acute cells, cells 
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without previous arsenic exposure, (+AS = With Arsenic and –AS = Without 
previous arsenic exposure).  
 
Column one of the pre-collagen coated 96 well plates was used for media 
alone, column two for media and cells, (cells grown in culture medium without 
arsenic which served as passage-matched control group), columns three to 
twelve for the various concentrations of ATO. Each of the concentrations was 
performed in triplicates. A total of 200 μL complete media only was added to 
the first column, then 100 μL of HaCaT cell suspension in complete media 
containing approximately 20,000 cells/well were added to columns two to 
twelve wells of the pre-collagen coated 96 well plates, 100 μL of media was 
added to column two and 100 μL of ATO concentrations were added to 
columns three to twelve ensuring that the final concentrations were 0, 1.0, 5.0, 
7.5, 10, 15 µg/ml respectively. They were incubated in a humidified incubator 
at 37 °C in a 5% CO2 for a period of 2 days, 5 days, 8 days and 15 days. 
Arsenic has a very short half-life of approximately 5 days, (Tokar et al. 2011) 
consequently, media and arsenic were replaced every 4 days to maintain 
arsenic concentration level and nutrient for the cells thus removing any 
confounding factor that may come from depleted nutrients and cell 
metabolism wastes. At each of the time points, the culture plate was removed 
from the incubator and 10 µl of the yellow MTT (3-(4, 5 diphenyltetrazolium 
bromide, a tetrazole) reagent was added to each of the wells and incubated at 
37 °C for four hours until purple formazan precipitate was visible. 100µl of the 
detergent reagent was added to each of the wells and kept in the dark at room 
temperature for 2 hours. The absorbance was measured at 570 nm wave 
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lengths using a microtiter plate reader (Fluoroskan II microplate reader 
Helsinki, Finland). LD10 and LD50 were determined from dose response curve. 
The experiment was repeated using chronic HaCaT cells (HaCaT that have 
been exposed to low dose 0.5 µg/ml ATO up to 10 passages).  
 
3.3.6 Single Gel Electrophoresis (Comet Assay) 
Comet Assay is a simple and effective way of evaluating DNA damage in 
cells. Denatured DNA fragments migrate out of the cell under the influence of 
an electric field whereas undamaged DNA migrates slower and remains within 
the confines of the nucleoid when a current is applied. The evaluation of the 
DNA “comet” tail shape and migration pattern is used to assess the level of 
DNA damage when visualized using an epiflourescence microscope. 
Experiment was done 4 replicates for 3 conditions; Unexposed HaCaT 
(Control) HaCaT exposed to 0.5µg/ml As2O3, passage 1, HaCaT exposed to 
0.5µg/ml As2O3, passage 22 (chronic exposure). 
 
The experiment was performed using a Comet assay kit (Trevigen Inc., 
Gaithersburg, MD). The manufacturer’s protocol was followed to conduct the 
experiment. About 1.5 ×105 HaCaT cells were cultured in 7.5ml of complete 
DMEM in T-25 culture flask and incubated in humidified atmosphere with 5% 
CO2 at 37 °C. After growing to 80% confluence the DMEM was aspirated and 
replaced with different concentrations of ATO diluted in complete DMEM (0, 1, 
5, 7.5, 10, and 15 µg/ml) and incubated for 48 hours. The untreated HaCaT 
Cells (0 µg/ml) served as the DNA damage control. After ATO treatments, the 
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medium was removed, and the cells were washed three times with pre-chilled 
PBS and trypsinised with 1 mL of 0.25% trypsin-EDTA, and the cells were 
transferred to a centrifuge tube and were counted. The cells were centrifuged 
at 3000 rpm for 5 min and washed ones in ice cold PBS. The pellet was re-
suspended in ice cold PBS at 1 × 105 cells/ml. The cells were mixed with 
molten LMAgarose (at 37 ºC) at a ratio of 1:10 (v/v), and 50 μL was 
immediately pipetted onto pre-coated CometSlideTM. The slides were placed 
flat in a refrigerator at 4 °C in the dark for 30 minutes. The slides were 
immersed in a pre-chilled lysis solution and left on ice for 60 minutes. Excess 
buffers were drained from the slides and then immersed in a freshly prepared 
alkaline solution, pH > 13 (0.6 g of NaOH pellets, 250 μL of 200 mM EDTA and 
49.75 mL of dH2O) for 60 minutes at room temperature. Slides were washed 
twice for 5 minutes with 1X TBE (Tris-Borate-EDTA neutral buffer) 
electrophoresis buffer. The slides were aligned equidistant from electrodes in a 
horizontal gel apparatus and 1X TBE was added and electrophoresed at 1 
V/cm (22 V) for 10 minutes. Excess TBE was tapped out and the slides were 
immersed twice in distilled water for 10 minutes and in 70% ethanol for 5 
minutes. Excess 70% ethanol was removed and the slides were air dried 
overnight and stained with 100 µL of diluted SYBR Green and were placed in 
the refrigerator for 5 minutes, removed, and tapped to remove SYBR Green. 
Slides were allowed to air dry at room temperature in the dark. The slides were 
examined using an Olympus Epifluorescence Microscope and the LAI’s 
Automated Comet Assay Analysis System (LACAAS) (Loates Associates, Inc. 
Westminster, MD) was used to determine the extent of DNA damage by 
measuring the percent DNA in the Tail (the integrated tail intensity x 100 / the 
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total integrated cell intensity for a normalized measure of the percent of total 
cell DNA found in the tail), (Woodgatte 2008) comet moment (% DNA in tail X 
tail length) and Tail Length (the distance of DNA migration from the body of the 
nuclear core). Loats System is an automated comet assay analysis system 
which enables objective quantitative studies of DNA damage, protection and 
repair and studies of apoptosis inducing mechanisms and agents. The 
advantages of using the Loats System include increase in analytic capacity, 
high turnaround time, improved data accuracy, reliability and traceability. It is 
equipped with fluorescent microscope with computer controlled servo-driven 
stage and focus and a high performance computer controlled thermo-
electrically cooled digital camera. And also, a robotic vacuum slide handling 
subsystem and windows based computer. The fully automated system version 
makes it possible to process unattended batch of multiple slides in a single 
run. Also, its proprietary extended dynamic range image acquisition feature 
avoids problems of camera saturation and thus providing more accurate 
quantitative data on cellular DNA distribution. Further, it has a locally adaptive 
background correction feature which eliminates detrimental effects of spatially 
varying non-specific fluorescence. The Loat System used in this study has a 
sophisticated image processing algorithms which provide automated 
delineation of comet head and tail and objective quantitative measures over 
full range of DNA damage. The Loats System is able to put all the comet 
images and derived measures into a database for subsequent review and 
statistical analysis. And it provides statistical summary reports immediately 
after analysis of slides. Seventy comets were randomly selected from each 
slide for statistical analysis and photographs were taken to show the changes 
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in DNA morphology due to exposure to ATO. Experiments were conducted in 
triplicates. 
 
3.4 Gene Expression studies in HaCaT Keratinocytes Chronically 
Exposed to ATO  
 
3.4.1 The experimental design:  
Two experimental groups; 
1.  The treatment group: HaCaT Cell treated with 0.5 µg/ml of ATO 
sub-cultured up to passage 22 to establish a chronic exposure 
state.  
2.  The passage control group: untreated HaCaT cell that were also 
sub-cultured up to 22 passages but with no exposure to ATO.  
There were 4 technical replicates with 3 replicates making a total of 8 
×3=24 samples.  
 
3.4.2 Treatment Dose Determination: 
The LD10 dose result obtained from the initial cytoxicity assay (Figure 6) was 
arbitrarily divided by 1/2 to get 0.5 µg/ml of ATO that was used for chronic 
dosage treatment.  
Working Solution Preparation: 
Stock solution: 1000 µg/ml (1000 µg/ml) ATO 
Working solution: 0.5 µg/ml (0.5 µg/ml) ATO 
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To make 10 ml of 0.5 µg/ml from 1000 µg/ml  
Concentration = Want/Have x Final volume 
0.5 µg/ml /1000 µg/ml x 10,000uL = 5uL 
1.5 ×105 HaCaT cells were cultured in 7.5 ml of complete DMEM containing 
10% Foetal Bovine Serum (FBS) and 1% penicillin, streptomycin in T-25 
culture plate. Cells were cultured in a humidified atmosphere with 5% CO2 at 
37 °C. The treatment groups were exposed to 0.5µg/mL ATO (equivalent to LC 
0.5), and passaged at 90% confluent. To establish a chronic exposure the 
treatment groups were sub-cultured up to passage 22. 
 
3.4.3  RNA Extraction and Gene Expression 
Total RNA was extracted from 4 technical replicates of unexposed HaCaT 
cells and HaCaT cells chronically exposed to ATO up to passage 22 using 
RNA STAT-60 (TEL-TEST, INC, Friendswood, TX, USA) (Chomczynski et al. 
1987). A NanoDrop ND-1000 spectrophotometer (NanoDrop products, 
Wilmington, DE) was used to quantify the RNA by optical density reading. 
Also, the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) was 
used to determine the purity and quality of the extracted RNA. Only high 
quality RNA, having a RNA Integrity Number (RIN) of >7.0, (Schroeder et al. 
2006) and an A260/280 absorbance ratio of >1.8, was utilized for microarray  
experiments. 
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3.4.4  Microarray Analysis 
3.4.4.1 Microarray Platform:  
The Human Whole Genome OneArray™ (Phalanx Biotech, Palo Alto, CA) 
platform (GEO Accession number GPL6254G) was used to perform DNA 
microarray analysis. The slide list as used for the experiment is illustrated in 
Table 5.  
 
3.4.4.2 Label Protocol:  
RNA was converted to double-stranded cDNA and amplified using in vitro 
transcription systems that included amino-allyl UTP, and the aRNA product 
was subsequently conjugated with Cy5™ NHS ester (GEH Life sciences, 
Pittsburgh, PA). 
 
3.4.4.3 Hybridization Protocol:  
Fragmented aRNA was hybridized at 42 °C overnight using the HybBag mixing 
system with 1X OneArray Hybridization Buffer (Phalanx Biotech, Palo Alto, 
CA), 0.01 mg/ml sheared salmon sperm DNA (Promega, Madison, WI, USA), 
at a concentration of 0.025 mg/ml labelled target. After hybridization, the 
arrays were washed according to the OneArray protocol.  
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3.4.4.4 Scan Protocol:  
Raw intensity signals for each microarray were captured using a Molecular 
Dynamics™ Axon 4100A scanner, measured using GenePixPro™ Software, 
and stored in GenePix Results (GPR) format.  
 
3.4.4.5 Data Processing - Normalization:  
The data from all microarrays in each experimental set was then passed to 
Rosetta Resolver (Rosetta Biosoftware, Seattle, WA) for analysis and it 
computed the normalised signal intensity. Pearson correlation tables (R 
values) for each technical repeats were generated. R values were calculated 
from raw log2 intensity (R) and normalized log2 intensity (N) values for each 
dataset and compared to each other. Only probes with P value (detected) less 
than 0.05 were included in the calculation. Individual pairwise comparisons 
were also performed to ascertain the level of consistency and to identify the 
top altered genes for each major comparison. 
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Table 5: Microarray Experiment; ATO treated vs. Untreated HaCaT cells 
Slide List 
 
Sample Sample_Label Chip_Barcode Chip_Label Note 
 
HaCaT Cell 
untreated UT H001-0606026753 H1_H001 
H1 
 
HaCaT Cell 
untreated UT H002-0606026754 H1_H002 
H1 
 
HaCaT Cell 
untreated UT H003-0606026743 H1_H003 
H1 
 
HaCaT Cell 
untreated UT H004-0606026110 H2_H004 
H2 
 
HaCaT Cell 
untreated UT H005-0606026112 H2_H005 
H2 
 
HaCaT Cell 
untreated UT H006-0606026113 H2_H006 
H2 
 
HaCaT Cell 
untreated UT H007-0606026747 H3_H007 
H3 
 
HaCaT Cell 
untreated UT H008-0606026748 H3_H008 
H3 
 
HaCaT Cell 
untreated UT H009-0606026749 H3_H009 
H3 
 
HaCaT Cell 
untreated UT H010-0606026764 H4_H010 
H4 
 
HaCaT Cell 
untreated UT H011-0606026765 H4_H011 
H4 
 
HaCaT Cell 
untreated UT H012-0606026766 H4_H012 
H4 
 
HaCaT Cell 
treated T H013-0606026767 A1_H013 
A1 
 
HaCaT Cell 
treated T H014-0606026768 A1_H014 
A1 
 
HaCaT Cell 
treated T H015-0606026769 A1_H015 
A1 
 
HaCaT Cell 
treated T H016-0606026124 A2_H016 
A2 
 
HaCaT Cell 
treated T H017-0606026125 A2_H017 
A2 
 
HaCaT Cell 
treated T H018-0606026126 A2_H018 
A2 
 
HaCaT Cell 
treated T H019-0606026750 A3_H019 
A3 
 
HaCaT Cell 
treated T H020-0606026770 A3_H020 
A3 
 
HaCaT Cell 
treated T H021-0606026759 A3_H021 
A3 
 
HaCaT Cell 
treated T H022-0606026751 A4_H022 
A4 
 
HaCaT Cell 
treated T H022-0606026757 A4_H022.1 
A4 
 
HaCaT Cell 
treated T H023-0606026752 A4_H023 
A4 
Where UT = Untreated; T= Treated, HaCaT = HaCaT Cell; A= HaCaT with 
Arsenic 
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3.4.5  Two-step quantitative qRT-PCR 
Relative quantitation using the comparative CT method (Livak et al. 2001) was 
employed to confirm the microarray gene expression data. Sample H1 
(untreated HaCaT cell) was used as calibrator and Beta glucuronidase 
(GUSB) as endogenous control gene for normalization. Applied Biosystems 
(Applied Biosystems, Carlsbad, CA) standard protocol was followed. The RNA 
samples were reverse-transcribed for 120 min at 37 °C with High Capacity 
cDNA Reverse Transcription Kit. Quantitative PCR was carried out for 10 min 
at 95 °C, and 40 cycles of 15 sec at 95 °C, 1 min at 60 °C using 2X Power 
SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) and 200 
nM of forward and reverse primers. The primers used and the quality control 
results are listed in the Appendix on page 127. Triplicates of each assay were 
run on an Applied Biosystems 7300 Real-Time PCR system and expression 
fold-changes were derived using the comparative threshold (CT) method. Each 
replicate cycle threshold (CT) was normalized to the average CT of GUSB on a 
per sample basis.  Applied Biosystems formula was used to calculate the 
relative amount of the transcripts in the arsenic treated HaCaT and the 
untreated sample H1 (control), and both were normalized to the endogenous 
control (GUSB): ΔΔCT = ΔCT (treated) - ΔCT (control), where ΔCT is the 
difference in CT between the target gene and endogenous controls by 
subtracting the average CT of controls. The fold-change for each treated 
sample relative to the control sample equals 2-ΔΔCT. 
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3.5 Statistical Analysis 
The absorbance values obtained per treatment from the MTT assay were 
converted to percentages of cell viability. Statistical analysis for differences in 
mean levels of ATO was done using the Student’s t-test for comparing two 
sample sets at p <0.05. The data generated from the Comet assay were 
analysed by the Student’s t-test by comparing the means of the treated and 
untreated control HaCaT cells, and the significance level was p <0.05. 
 
3.6 Bioinformatics analyses 
The following bioinformatics tools and data bases where used in this 
study; 
 
3.6.1  Visual Analysis Method 
Tools available in the Tableau Public Software 
(http://www.tableausoftware.com/public) were used to construct interactive 
views of the cytotoxicity and genotoxicity data produced from the experimental 
results. 
 
3.6.2 Biological Pathway Modelling 
Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Redwood City, CA) was 
used to determine models of biological pathways and networks that were 
significantly represented in the differentially expressed (both up and down 
regulated) genes. 
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IPA identifies networks and pathways represented in the gene lists of interest. 
It generates a P-value for each network and canonical pathway, which is the 
likelihood that a given network was identified by chance. Networks scoring ≥ 2, 
which have > 99% confidence of not being generated by chance, were 
selected (Gerling et al. 2006). 
 
IPA assigns biological functions to each network by using annotations from 
scientific literature and stored in their knowledge base.  Fisher exact test was 
used to calculate the P-value for each biological function/disease or pathway 
being assigned by chance. Also, Benjamini-Hochberg corrected P ≤ 0.05 was 
used to select highly significant biological functions and pathways represented 
in the datasets analysed (Gerling et al. 2006). 
 
3.6.3 Prediction of cysteine state and disulphide bond partners  
The cysteine state and disulphide bond partners in protein sequences were 
predicted using DiANNA (Ferre et al. 2005;Ferre et al. 2006), DBCP (Lin et al. 
2010) and DISULFIND (Ceroni et al. 2006). DiANNA is a unified software for 
Cysteine state and Disulphide Bond partner prediction available at 
http://clavius.bc.edu/~clotelab/DiANNA/. The output include the following; 
positions of cysteine, positions of oxidized cysteine, predicted disulphide 
bonds, and predicted positions of cysteine in metal binding site (Ferre et al. 
2006). The Disulphide Bonding Connectivity Pattern (DBCP) provides 
prediction without the prior knowledge of the bonding state of cysteine. 
http://140.120.14.136/dbcp/ (Lin et al. 2010). The output of the DISULFIND 
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server (http://disulfind.dsi.unifi.it/) is a simple visualization of the assigned 
bonding state (with confidence degrees) and the most likely connectivity 
patterns (Ceroni et al. 2006).  
 
3.6.4 Prediction of Biological Networks  
The Michigan Molecular Interactions (MiMI) plugin for Cytoscape (Gao et al. 
2009) was used to retrieve molecular interactions and interaction attributes in 
the Michigan Molecular Interactions (MiMI) for query genes and their nearest 
neighbours. The Cytoscape platform was used to display the biological 
networks with the biological entities (genes/proteins) represented as nodes 
and the biological interactions represented as edges between nodes (Cline et 
al. 2007;Smoot et al. 2011;Tang et al. 2012). 
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Chapter 4 
Results 
4.1  Cytotoxicity Assay 
Cytotoxicity MTT assay showed that acute exposure of HaCaT cells to arsenic 
had LD10 and LD50 values of 1 µg/ml and 10 µg/ml respectively (Figure 6). 
The LD10 dose result obtained from the initial cytotoxicity assay (Figure 6) 
was arbitrarily divided by 1/2 to get 0.5 µg/ml of Arsenic that was used for 
chronic dosage treatment.  
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Figure 6: Cytotoxicity Assay (MTT) of HaCaT cell line showing LD50  
Acute exposure of HaCaT cells to varying concentrations of ATO 
to determine the lowest tolerable concentration to be used for 
chronic exposure studies. 
 
4.2 Cytotoxicity and Chronic Toxicity Assay 
The MTT Assay II was used to evaluate cytotoxicity and chronic toxicity 
patterns of ATO on HaCaT keratinocytes. Long-term cultures were 
established by culturing HaCaT cells on collagen IV. The LD10 value of 1µg/ml 
obtained from the MTT I assay was arbitrarily divided in half to get 0.5 µg/ml 
dose used to establish the chronic HaCaT cells. HaCaT cells exposed to ATO 
up to 8 passages were considered chronic.  
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4.2.1 Acute Exposure 
Three visual analytics representations of the cell viability data are presented in 
Table 6, Figure 7 and Figure 8. Time course cell viability pattern, showing 
acute vs. chronic exposure to ATO is illustrated in Figure 7. Chronic HaCaT 
cells were more tolerant to the 5 µg/ml dose compared to the acute HaCaT 
cells.  A low dose of 1 µg/ml was observed to improve cell viability while high 
doses above 5 µg/ml were toxic to both chronic and acute HaCaT cells. Figure 
7 presents a time course for each dose while Figure 8 presents a view 
comparing the exposure types for each time point and concentration. In 
addition, Figure 9 and Figure 10 present the cytotoxicity data as a bar chart 
with error bars showed. Overall in both acute and chronic exposure, the 
HaCaT cell viability was dose dependent. Thus an increase in dose resulted in 
decreased cell viability. The 1 µg/ml  dose in the acute treatment cells resulted 
in 92.4% viability on Day 2 and cells continued to grow in the time course with 
viability rates of 93.4%, 107% and 115.9% for Day 5, Day 8 and Day 14 
respectively (Figures 5, 6, and 7). The 5 µg/ml concentration resulted in 
viability rates of 30.8%, 36%, 46.7% and 32.7% for the time points.  
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Table 6: HaCaT/Arsenic Viability Table showing Chronic vs. Acute 
Exposure 
Day Concentration Exposure 
  Acute (%) Chronic (%) 
Day 2 0 µg/ml 100 100 
 1 µg/ml 92.4 92.1 
 5 µg/ml 30.8 42.9 
 7.5 µg/ml 23.8 27.1 
 10 µg/ml 17.1 20.4 
 15 µg/ml 13.4 14.7 
Day 5 0 µg/ml 100 100 
 1 µg/ml 93.4 98.5 
 5 µg/ml 36.0 45.9 
 7.5 µg/ml 23.3 30.2 
 10 µg/ml 17.3 25.2 
 15 µg/ml 11.8 17.3 
Day 8 0 µg/ml 100 100 
 1 µg/ml 107.0 114.5 
 5 µg/ml 46.7 67.1 
 7.5 µg/ml 15.6 20.3 
 10 µg/ml 10.0 10.8 
 15 µg/ml 6.3 7.2 
Day 14 0 µg/ml 100 100 
 1 µg/ml 115.9 120.0 
 5 µg/ml 32.7 56.7 
 7.5 µg/ml 15.6 20.9 
 10 µg/ml 8.0 10.1 
 15 µg/ml 5.8 7.4 
Notes: Data in table can be downloaded at: 
http://public.tableausoftware.com/views/hacat_arsenic_3/viability_table 
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Figure 7: Dose and time dependent response to the cytotoxic effect of 
ATO on HaCaT keratinocytes.  
The 1 µg/ml dose encouraged growth in both acute and chronic 
cells while higher doses caused cell death. 
 Interactive visual analytics resource for image available at 
http://public.tableausoftware.com/views/hacat_arsenic_3/viability_
timecourse 
 
4.2.2 Chronic Exposure 
Treatment doses of 7.5 µg/ml, 10 µg/ml and 15 µg/ml inhibited growth of 
chronic cells (Figure 8). In the chronic treatment cells, the 1 µg/ml  dose gave 
viability rates of 92.1%, 98.5%, 114.5% and 120% for days 2, 5, 8, and 14 
respectively, while the 5 µg/ml  gave viability rates of 42.9%, 45.9%, 67.1% 
and 56.7% for days 2, 5, 8, and 14 respectively (Figures 7, 8, and 10). The 
chronic cell had higher viability values that could resist the cytotoxic effect of 
the high doses of 7.5µg/ml, 10µg/ml and 15µg/ml. There was no significant 
difference at p <0.05 when the chronic HaCaT cells were compared with the 
acute HaCaT cells at the various time points except for 5 µg/ml  dose using 
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student’s t-test. Additionally, there was no significant difference when the 
controls were compared with the 1 µg/ml dose in both acute and chronic cells 
at p <0.05. However, there are significant differences at p <0.05 on Day 2 
between the controls and other treatment groups; 5µg/ml, 7.5µg/ml, 10µg/ml 
and 15µg/ml in both acute and chronic cells. 
 
  
Figure 8: Time course cell viability pattern, showing acute vs. chronic 
exposure to ATO. Previous exposures appear to confer some 
level of protection to chronic cells than acute cells. 
 Interactive visual analytics resource for image available at 
http://public.tableausoftware.com/views/hacat_arsenic_3/viability_
figure 
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Figure 9: Dose and time dependent response of HaCaT keratinocytes 
without prior exposure to low dose (0.5 µg/ml) of ATO over 10 
passages (static image with error bars).  The 1.0 µg/m dose 
appears to stimulate cell growth while higher concentrations 
caused cell death  
 
 
 
Figure 10: Dose and time dependent response of HaCaT keratinocytes 
with prior exposure to low dose (0.5 µg/ml) of ATO over 10 
passages (static image with error bars).  
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4.3  DNA Damage Assay (Comet Assay) 
Comet assay was performed in HaCaT cells exposed to different 
concentrations of ATO to determine the dose that has the highest genotoxic 
effect. Comet assay was done using TBE, a neutral buffer which produces 
elongated comet shape, stained with SYBR® Green and images generated 
and measured automatically on Loats System. The parameters measured in 
the 70 comets randomly selected per sample were the moment, comet tail 
length and DNA damage. There was an increase in the length and rate of 
DNA migration in the HaCaT cells treated with ATO when compared with the 
untreated control HaCaT cell.  The comet assay result shows a dose 
dependent response to ATO exposure as shown in Figure 11. The % DNA 
damage results were 0.27, 3.45, 3.22, 4.0, 7.5 and 11 for the 0 µg/ml, 1 µg/ml, 
5 µg/ml, 7.5 µg/ml, 10 µg/ml and 15 µg/ml respectively. There was a 
significant difference in DNA damage between the control and the treatment 
doses at (p<0.05) using F-Test two-sample for variance. A similar pattern was 
observed for comet moment and comet tail length results. Images 
representing the comets observed are shown in Figure 12 and values in Table 
7. In Figure 12, Panel A represents a comet from the untreated cell control; 
Moment 0.0, %DNA 0.08, Length 0.0. Panel B represents 1 µg/ml; Moment 
0.04, %DNA 2.1, Length 5, and Panel C; 15 µg/ml; Moment 8.18, %DNA 
28.62, Length 73.  A remarkable increase in the length of DNA migration and 
the rate of DNA migration of the HaCaT cells were observed in the chronically 
exposed passage 22 HaCaT dose (0.5µg/ml) (p<0.05). There was no 
significant difference (p>0.05) between the passage 1 and the untreated 
HaCaT cell (control). This was analysed using general linear model (GLM) 
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procedure of SAS (9.1v). Thus, long term exposure of low dose, 0.5 µg/ml 
ATO on HaCaT cell line is genotoxic (p<0.05). 
 
Table 7: Summary of Comet Assay data showing percentage DNA damage 
of HaCaT cells exposed to ATO*      
  Comet 
Concentration % DNA Length Moment 
0.0 µg/ml 0.27 2.00 0.26 
1.0 µg/ml 3.45 3.00 0.97 
5.0 µg/ml 3.22 4.50 1.03 
7.5 µg/ml 4.00 4.50 5.00 
10.0 µg/ml 7.50 6.50 2.34 
15.0 µg/ml 11.0 10.00 9.00 
Notes: Data in table can be downloaded at: 
http://public.tableausoftware.com/views/hacat_arsenic_3/comet_table 
 
 
 
 
Figure 11: Genotoxic effect of ATO on HaCaT keratinocytes with Comet 
assay (static image with error bars).  The higher the concentration 
of arsenic, the higher the DNA damage on HaCaT cells. 
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Figure 12: Representative comets from exposure of HaCaT keratinocytes 
to concentrations of ATO  
 
4.4 Gene Expression of HaCaT keratinocytes 
4.4.1 RNA Quality Control Results 
The RNA quality control were obtained using Agilent 2100 Bioanalyzer and the 
Agilent 2200 Tape Station and the result analyses were displayed in form of 
tables, electropherograms and gel images. As shown in Table 8, total RNA per 
sample ranges from 35.2 µg to 90.9 µg and each of them exceeded the 6 µg to 
12 µg requirements for aRNA preparation method and 50 µg for cDNA 
preparation method. The optical density of the total RNA was measured by 
NanoDrop ND-1000. The RNA purity was estimated by taking the ratio of 
absorbance at 260 nm and 280 nm and ratios between 1.8 and 2.2 indicate a 
pure sample. Also, as shown in Table 9, all the samples have 260 nm/280 nm 
ratios of 1.90 to 2.01. RNA Integrity Number (RIN) algorithm assigns a 1 to 10 
RIN score, where level 10 RNA is completely intact. The RIN should be above 
7 to get a reliable and acceptable microarray result. All the samples as shown 
in Table 8 have RIN of 10. RIN score was given by Agilent RNA 6000 Nano 
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Assay. To get a good and reliable microarray result, the labelling efficiency 
must be above 10. As demonstrated in Table 9, all the samples labelling 
efficiency values are above 10. The purified aRNA/cDNA was conjugated with 
the NHS-CyDye using reactive amino group of 5-(3-aminoallyl)-UTP/5-(3-
aminoallyl)-dUTP.  And the labelling efficiency was calculated by the 
concentration of CyDye and aRNA/cDNA measured by NanoDrop ND-1000. 
Agarose electrophoresis was performed to determine if there serious DNA 
contamination. Figure 13 shows that there was no DNA contamination in the 
samples. 
 
Table 8: AminoAllyl aRNA Quality Control Result 
Item Sample Name OD260/280 
1.8 
Total 
Amount 
(µg) 
6 µg 
RIN 
7.0 
QC Result 
Pass or 
Fall 
Note 
1 HaCaT Cell 
untreated 
2.01 90.9 10.0 Pass H1 
2 HaCaT Cell 
untreated 
1.95 71.6 10.0 Pass H2 
3 HaCaT Cell 
untreated 
1.91 46.8 10.0 Pass H3 
4 HaCaT Cell 
untreated 
1.92 35.2 10.0 Pass H4 
5 HaCaT Cell treated 1.92 43.4 10.0 Pass As1 
6 HaCaT Cell treated 1.90 59.4 10.0 Pass As2 
7 HaCaT Cell treated 1.93 6.4 10.0 Pass As3 
8 HaCaT Cell treated 1.94 42.9 10.0 Pass As4 
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Table 9: AminoAllyl a RNA and Labelling QC Result 
Item Sample Name OD260/280 
>1.8 
Labelling 
Efficiency 
Cy5 > 10 
Quality 
Pass or Fail 
1 HaCaT Cell 
untreated 
2.03 32.7 Pass 
2 HaCaT Cell 
untreated 
2.04 44.6 Pass 
3 HaCaT Cell 
untreated 
2.02 36.2 Pass 
4 HaCaT Cell 
untreated 
2.01 36.5 Pass 
5 HaCaT Cell treated 2.01 32.1 Pass 
6 HaCaT Cell treated 1.98 30.7 Pass 
7 HaCaT Cell treated 2.04 30.5 Pass 
8 HaCaT Cell treated 2.04 30.5 Pass 
   Note: Labelling Efficiency: # dye molecules/per 1000 nucleotides 
 
 
Figure 13: RNA Quality Control Gel  
(M=ladder, 10,11,12,13 = Untreated HaCaT Cells; 14, 15, 16, and 17=Arsenic 
Treated HaCaT Cells) 
 
The Electropherogram of total RNA (Figure 14) shows the ribosomal RNA 
peaks are at a ratio of about 2 (28S:18S) suggesting that the RNA integrity are 
or ultrahigh quality. 
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Figure 14: Electropherogram of total RNA of human Skin Keratinocytes 
(HaCaT) Quality Control Report (Report generated from 
Bioanalyzer 2100 Agilent, USA) 
 
 
4.4.2 Global Gene Expression 
The criterion for selection of differentially expressed genes (DEGs) was a fold 
change greater than or equal to 2. Comparison of the microarray data from 
untreated (control) and chronically exposed HaCaT keratinocyte cell identified 
35 differentially expressed genes of interest with 14 genes up-regulated 
(Table 10) and 21 genes down-regulated (Table 11). Genes with ≥ 2 fold 
changes and P-value ≤ 0.05 were considered significantly expressed and 
were selected for confirmation using qRT-PCR. The functional annotations 
including Gene Ontology for these genes were determined using the Michigan 
Molecular Interactions (MiMI) web tool (Tarcea et al. 2009) 
(http://mimi.ncibi.org/).  
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Table 10: Genes up-regulated in response to chronic-dose exposure of 
ATO to HaCaT keratinocyte cells 
Gene Symbol Gene Description 
AGPAT4  1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid 
acyltransferase, delta)  
AKR1C2  
 
aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile 
acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)  
AKR1C3  aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II)  
C22orf42  Uncharacterized protein C22orf42  
GLT6D1 glycosyltransferase 6 domain containing 1  
IGFL1  IGF-like family member 1 
IL1R2  interleukin 1 receptor, type II  
KLHDC8A Kelch domain-containing protein 8A   
NQO2 NAD(P)H dehydrogenase, quinone 2  
PCSK1  proprotein convertase subtilisin/kexin type 1  
STRAP  STRAP serine/threonine kinase receptor associated protein 
TMEM70 Transmembrane protein 70  
TNFSF18  tumor necrosis factor (ligand) superfamily, member 18  
ZFP36L1 zinc finger protein 36, C3H type-like  
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Table 11: Genes down-regulated in response to chronic-dose exposure of 
ATO to HaCaT keratinocyte cells 
Gene Symbol Gene Description 
CCDC150  coiled-coil domain containing 150  
CLCC1 Chloride channel CLIC-like 1  
CSRP1  Cysteine and glycine-rich protein 1  
FGF1 fibroblast growth factor 1 (acidic)  
GCNT3 Glucosaminyl (N-acetyl) transferase 3, mucin type  
GDA  Guanine deaminase  
HOXA5 homeobox A5  
IMP5  Signal peptide peptidase-like 2C Precursor  
(Protein SPP-like 2C)(Protein SPPL2c)(EC 3.4.23.) (Intramembrane protease 
5)(IMP5)  
MAK male germ cell-associated kinase  
MKNK1 MAP kinase interacting serine/threonine kinase 1  
MRC2 mannose receptor, C type 2  
NP153 nucleoporin 153kDa  
NT5C 5', 3'-nucleotidase, cytosolic  
PHF12 PHD finger protein 12  
PPP1R13B  Apoptosis-stimulating of p53 protein, protein phosphatase 1, regulatory 
(inhibitor) subunit 13B  
PRKAR1B protein kinase, cAMP-dependent, regulatory, type I, beta  
RASL10A  RAS-like, family 10, member A  
RGS2 regulator of G-protein signalling 2, 24kDa  
TM4SF4  transmembrane 4 L six family member 4  
TOM1 target of myb1 (chicken)  
ZNF19 zinc finger protein 19  
 
 
4.4.3  Quantitative PCR confirmation of microarray data  
Relative quantitation using the comparative CT method was used to confirm 
the microarray gene expression data. The genes expressed for the RNA of 
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arsenic treated cells were compared with the reference untreated control 
sample. The qRT-PCR confirmed the expression of 4 up-regulated genes and 
1 down-regulated gene for genes with a fold change of ≥ 2. The up-regulated 
genes were AKR1C3 (9.2 fold), IGFL1 (3.1), IL1R2 (5.9 fold), and TNFSF18 
(167 fold) and down-regulated gene was RGS2 (2.0 fold). A visualization 
comparing the fold change obtained by microarray and qRT-PCR for 9 genes 
is presented in Figures 15. 
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Figure 15: Comparison of fold change between microarray data and qRT-
PCR data. Most of the upregulated genes in the microarray 
experiment were confirmed by qPCR. 
(Red: up-regulated; yellow: unchanged; green: down-regulated). 
 
4.5 Biological pathway analysis 
The functional and pathway annotation analysis to identify specific pathways 
of interest from the microarray gene expression datasets was performed using 
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Ingenuity Pathway Analysis tool (IPA; Ingenuity Systems, Redwood City, CA).  
Figure 16 shows the pathways affected by arsenic exposure with the most 
affected being Liver X Receptor /Retinoid X Receptor (LXR/RXR) pathway 
which are involved in lipid metabolism and immune response (Christoffolete et 
al. 2010;Laffitte et al. 2003). IPA was also used to determine models of 
biological pathways and networks that are significantly represented in the 
differentially expressed (both up and down regulated) genes.  Benjamini-
Hochberg corrected P ≤ 0.05 is used to select highly significant biological 
functions and pathways represented in the datasets (Borch et al. 1992). Gene 
functional pathways and interactions for IL1R2, TNFSF18 and AKR1C3 were 
generated using Ingenuity Pathway Analysis tool as presented in Figure 17, 
Figure 18 and Figure 19 respectively. These genes were up-regulated in 
response to chronic-dose exposure of ATO to HaCaT cells as documented in 
Table 10. Molecules in red are up-regulated while molecules in green are 
down-regulated in the microarray data. Figure 17 network suggests molecules 
that could be involved in ILR2 expression under chronic arsenic exposure. 
There is an interaction between IL1A, IL1B, IL1RAP and GLI1 with IL1R2. 
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Figure 16: Canonical Pathways most affected by Arsenic exposure  
The Liver X Receptor /Retinoid X Receptor (LXR/RXR) Activation is the 
most enriched 
 
 
 
 
 
94 
 
 
Figure 17: Interaction network of Interleukin 1 Receptor, Type II (IL1R2). 
IL1R2 up-regulation may activate the expression of the other 
molecules in its network 
(Molecules in red are up-regulated while molecules in green are 
down-regulated in the microarray analysis data). 
 
 
 
Figure 18: Interaction network for TNFSF18 interaction network. TNFSF18 
up-regulation may activate the expression of the other molecules 
in its network  
(Molecules in red are up-regulated while molecules in green are 
down-regulated in the microarray data) 
 
95 
 
 
 
 
 
Figure 19: Interaction network for AKR1C3; AKR1C3 up-regulation may 
activate the expression of the other molecules in its network  
(Molecules in red are up-regulated while molecules in green are 
down-regulated in the microarray data) 
 
Figure 19 shows that AKR1C3 is associated with biological pathways which 
are involved in thyroid hormone response, lipid and carbohydrate metabolism, 
growth and cell proliferation. AKR1C3 is highly up-regulated, and it is obvious 
from its interaction network that other molecules involved in that network are 
also up-regulated, suggesting that AKR1C3 up-regulation may  activate the 
expression of the other molecules in its network. For example, activation of 3-
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beta hydroxysteroid dehydrogenase, 3b-hsd, (or prostaglandin F synthase) 
might be activating AKR1C3.  
As illustrated in Figure 18, TNFSF18 networks with TNF and a transcription 
factor (Nuclear Factor 1) but expression of TNFSF18 could also trigger the 
expression of IL2 and TNF. Molecules in Green are down-regulated in the 
microarray data.  
 
Figures 20 and 21 illustrate Nuclear Receptor Pathways Affected as Predicted 
by Ingenuity Pathway Analysis. Liver X Receptor/Retinoid X Receptor 
(LXR/RXR) Pathway is the most affected pathway that is involved in lipid 
metabolism and immune response.  Thyroid Hormone/Retinoid X Receptor 
(TR/RXR) Pathway is highly involved in lipid metabolism, growth and cell 
proliferation and has been shown to be perturbed by ATO (Figure 20). 
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Figure 20: AKR1C3 is activated by the Thyroid Hormone/Retinoid X 
Receptor (TR/RXR) Activation Pathway involved in lipid 
metabolism (enriched by ATO exposure).  
Colour genes are differentially expressed in the microarray data 
(red: up-regulated, green: down-regulated). 
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Figure 21: Close up of Figure 20, Thyroid Hormone/Retinoid X Receptor 
(TR/RXR) Activation Pathway highlighting the interaction with 
AKR1C3 which was up-regulated in response to chronic-dose 
exposure to ATO.  
Colour genes are differentially expressed in the microarray data 
(red: up-regulated, green: down-regulated). 
 
4.6  Arsenic Up-regulated Membrane Proteins 
The membrane plays a role in determining the function of proteins by 
modulating protein function through localization with the substrate, activator, 
or downstream target, and activation of the protein by a conformational switch 
(Johnson et al. 1999). Two genes (IL1R2 and TNFSF18) from microarray 
gene expression results are focused on because they encode membrane 
proteins. The rationale for this focus is that membrane localized proteins could 
bind with arsenic at the cell surface and lead to subsequent changes in 
cellular biological pathways. 
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4.7 Prediction of cysteine state and disulphide bond partner  
Table 12 presents results of the cysteines state and disulphide bond partner 
prediction using the four properties disulphide bonds, half cystine, free 
cysteine and metal bonded cysteines. All the tools predicted the same number 
of cysteines and positions of the cysteines in the sequences. IL1R2 protein 
sequence had 9 cysteines residues, while TNFSF18 protein sequence had 6 
cysteines residues. However, the prediction software disagreed on the 
speciation of the cysteines. DBCP detected 2 cysteines with metal binding 
sites in TNFSF18. For TNFSF18, the DISULFIND predicted 6 half cystines 
while DiANNA predicted only 1 half cystine. Both DISULFIND and DiANNA 
predicted 3 disulphide bond formations whereas DBCP tool predicted no 
disulphide bond formation in TNFSF18. In IL1R2, the DISULFIND predicted 8 
half cystine and 1 free cysteine, the DiANNA predicted 2 half cystines and 7 
free cysteines while the DBCP predicted 4 half cystine and 5 free cysteines.  
The three bioinformatics software that predicted disulphide bond formation 
differed in the cysteines involved in the linkages (Table 12). Based on the 
agreement of software for disulphide bond prediction, we prioritized for further 
investigation the disulphide bond Cys152-Cys207 in IL1R2 and disulphide 
bond Cys24-Cys80 in TNFSF18.  
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Table 12: Prediction of disulphide bond partner and cysteine states for 
TNFSF18 and IL1R2 
*Disulphide bonds in bold are where two or three prediction software agree. 
 
4.8   Prediction of Biological Networks  
Genes for Interleukin 1 Receptor, type II (IL1R2) and Tumour Necrosis Factor 
(ligand) Superfamily, member 18 (TNFSF18) are part of ligand-receptor 
systems that encode membrane proteins. It is assumed that the predicted 
molecular interactions for IL1R2 will have connections to ligands IL1B and 
IL1A (Mantovani et al. 1998) while TNFSF18 will have connection to its 
receptor TNFRSF18 (Krausz et al. 2007). The human IL1R2 and TNFSF18 
sequences were retrieved from UniProtKB/Swiss-Prot database with ID: 
IL1R2_HUMAN (P27930) and TNF18_Human (NP_005083.2) respectively. 
The IL1R2_HUMAN sequence was retrieved in FASTA format and used for 
analysis (Figure 22).  
 
The Michigan Molecular Interactions (MiMI) plugin for Cytoscape (Gao et al. 
2009) was used to retrieve molecular interactions and interaction attributes in 
the Michigan Molecular Interactions (MiMI) for query genes IL1B, IL1R2, IL1A, 
Software and Protein Predicted disulphide bonds* 
Half  
cys 
Free 
Cys 
Metal 
Bonded 
DiANNA – TNFSF18 10-100, 24-80, 52-61 1 5 0 
DISULFIND  – TNFSF18 10-61, 24-80, 52-100 6 0 0 
DBCP – TNFSF18 10-61, 24-80, 52-100 0 4 2 
DiANNA – IL1R2 28-373, 50-116, 152-207, 258-326 2 7 0 
DISULFIND – IL1R2 28-116, 50-152, 108-326, 207-258 8 1 0 
DBCP– IL1R2 28-108, 152-207 4 5 0 
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TNFSR18 and TNFSF18 and their nearest neighbours. The Cytoscape 
platform was used to display the biological networks with the biological 
entities (genes/proteins) represented as nodes and the biological interactions 
represented as edges between nodes (Cline et al. 2007;Smoot et al. 2011). 
 
4.9 Predicted Arsenic-Modulated Molecular Networks Affecting Onset 
of Keratinocyte Differentiation 
 
The reconstructed molecular networks revealed interconnections to E2F4, an 
oncogenic transcription factor, predominantly expressed at the onset of 
keratinocyte differentiation. These genes can provide insights into the mode of 
action of arsenicals as well as discover gene and protein biomarkers of effects 
of arsenicals on human health. Figure 22 Illustrates Interaction Map for IL1B, 
IL1R2, IL1A, TNFSR18 and TNFSF18 reveals E2F4 Transcription Factor as 
link between sub-networks. E2F4 controls cell cycle and acts on tumour 
suppressor proteins. The molecular interaction map also predicted Necdin 
(NDN) as the connection between E2F4 and IL1A. TNF receptor associated 
factor 2 (TRAF2) was predicted as the connection between E2F4 and 
TNFSR18. The Activating Transcription Factor-2 (ATF2), a sequence-specific 
DNA-binding protein was predicted to interact with both E2F4 and IL1B. The 
reconstructed network consists of a total of 24 nodes.  
 
102 
 
 
Figure 22: Interaction Map for IL1B, IL1R2, IL1A, TNFSR18 and TNFSF18. 
The map reveals E2F4 Transcription Factor as link between sub-
networks. E2F4 controls cell cycle and acts on tumour suppressor 
proteins. 
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Chapter 5 
Discussion  
Chronic cultures of HaCaT cells were established using a low dose of 0.5 
µg/ml of ATO derived from cytotoxicity (MTT) Assay (Figure 6 on page 76).  
HaCaT cells were considered chronic after treated with 0.5 µg/ml ATO up to 
eight passages. The chronic HaCaT cells and untreated control HaCaT cells 
were subsequently exposed to higher doses of ATO. Bioinformatics tools and 
softwares were used to analyse the data and construct interactive 
visualizations of the acute and chronic exposures at the various time points 
(Figures 7 page 79 and Figure 8 page 80) and to demonstrate the genotoxic 
effect of arsenic on HaCaT cells (Figures 9 and Figure 10 on page 81). The 
visual analytics resources in this report unlike the standard static figures will 
allow for user-defined queries beyond those reported here. The visualizations 
could help generate hypothesis from novel insights on the patterns of arsenic 
cytotoxicity as the cells mature and differentiate from basal cell to squamous 
cells.  
 
The cytotoxicity results reaffirm that ATO is cytotoxic to HaCaT cells (Graham-
Evans et al. 2004). A biphasic response was observed at 5 µg/ml doses with 
cell viability peaking on Day 8 in both chronic cells and acutely exposed cells. 
It is obvious that a low dose of 1 µg/ml ATO enhanced HaCaT keratinocyte 
proliferation and doses above 7.5 µg/ml inhibited growth. This observation 
concurs with previous reports (Graham-Evans et al. 2004;Liao et al. 2004) but 
the time course profiling of ATO cytotoxicity using long-term HaCaT cell 
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cultures provides an approach to model the human epidermal cellular 
response to varying doses of ATO exposure. The behavior of the 1 µg/ml dose 
is similar to that previously observed with low micromolar concentrations of 
sodium arsenite. A very low dose of sodium arsenite maintained the 
proliferative potential of epidermal keratinocytes, and decreased their exit from 
the germinative stage under conditions that enable differentiation of untreated 
cells. Germinative cells are targets of tumour initiators and promoters and their 
persistence and proliferation after arsenic exposure suggests 
that arsenic could have co-carcinogenic and tumor co-promoting activities in 
the epidermis (Patterson 2005). Also, low concentrations of ATO may regulate 
the expression of cell cycling pathway genes such as cyclin-dependent kinase 
4 (CDK4) and transcription factor 1 (E2F1) (Bi et al. 2010) and this may 
explain the observation with 1 µg/ml dose. A molecular level interpretation of 
the induction of growth of cells by low arsenic concentration could be linked to 
the up-regulation of insulin growth factor like family member 1( IGFL1) as 
observed in the microarray gene expression experiment (Figure 13 on page 
86) in which HaCaT cells were exposed to low dose 0.5 µg/ml of ATO up to 22 
passages (Udensi et al. 2011a). IGFL1, like other related insulin growth factors 
(IGF), is involved in cellular energy metabolism, growth and development and 
promotion of cell division (Emtage et al. 2006). IGFL1 is frequently up-
regulated in skin conditions such as psoriasis which promote the abnormal 
proliferation and differentiation of epidermal keratinocytes (Lobito et al. 
2011;Tonel et al. 2009). Another factor that may stimulate increase in cell 
proliferation at 1 µg/ml dose could be the induction of cyclin D1 transcription by 
low dose arsenic as reported by Hwang et al., (Hwang et al. 2006). Cyclin D1 
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stimulates growth by shifting the G1 growth phase into the S/G2 cell cycle 
compartment. A similar observation had been made with ATO on porcine 
aortic endothelial cells (PAEC), in which low concentrations stimulated cell 
proliferation with increases in superoxide and hydrogen peroxide (H2O2) 
accumulation, H2O2-dependent tyrosine phosphorylation, and NF-κB-
dependent transcription (Barchowsky et al. 1999;Lee 2005).  
 
Genotoxic capability of ATO on HaCaT keratinocytes was observed using the 
Comet Assay on section 4.3, page 82. There was a significant difference 
between the control cell and the 1 µg/ml dose in the Comet assay (p<0.05) 
(Figure 10, page 81). The results show that ATO has differential effects on cell 
growth and DNA damage depending on its concentration and corroborates 
with other investigations using different cell lines other than HaCaT cell line 
(Andrew et al. 2006;Shi et al. 2004;Stevens et al. 2010). Arsenic dose 
dependent effects has been observed on telomerase activity in human 
promyelocytic leukaemia cells (HL-60) and HaCaT cells where low doses 
result in an increase in activity observed as elongated telomere length and 
promotion of cell proliferation. At high doses of arsenic, telomerase activity 
was reduced with reduced telomere length and cell death (Zhang et al. 2003). 
Telomere homeostasis is critical in maintaining chromosome and genomic 
stability (Misri et al. 2008;Viscardi et al. 2005). Another cell line that 
proliferates under the influence of low dose arsenic exposure is normal non-
transformed NHEK. Arsenite was reported to induce cell proliferation by 
increasing redox-related gene expression and decreasing DNA repair 
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(Hamadeh et al. 2002). Therefore, low concentrations of ATO can significantly 
enhance HaCaT keratinocyte proliferation.  
 
Global gene expression (section 4.4 on page 84) was performed to understand 
ATO mechanism of action from the induction of aberrations in gene expression 
perspective. All the RNA samples used for this study were of high quality with 
RIN of 10 as shown in Table 8, page 85. A comparison of the microarray data 
from untreated (control) and chronically exposed HaCaT keratinocyte cell 
identified a total of 35 differentially expressed genes with 14 genes up-
regulated (Table 10, page 88) and 21 genes down-regulated (Table 11, page 
89). Genes with ≥ 2 fold changes and P-value ≤ 0.05 were considered 
significantly expressed and were selected for confirmation using 
complementary qRT-PCR approach. The global transcriptomics approach 
identified 167 fold over expression of TNFSF18 (tumour necrosis factor 
(ligand) superfamily, member 18), 5.9 fold for IL1R2 (Interleukin 1 receptor, 
type 2), IGFL1 (Insulin Growth Factor-Like family member 1) (3.1 fold), and 
AKR1C3 (Aldo-Keto Reductase family 1, member C) (9.2 fold). Also, a 
decreased expression of RGS2 (Regulator of G-protein Signalling 2) (2.0 fold) 
was confirmed (see Figure 13, page 86). This suggests that low dose arsenic 
exposure induces immunotoxic, anti-differentiation, growth factor promotion 
and anti-apoptotic effects in skin keratinocytes (Martinez et al. 2011).   
 
IL1R2 also referred to as CD121b, IL1RB, and MGC47725 (Dale et al. 1999) 
plays a vital role in immune response and it is associated with the membrane 
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(Figure 15, page 90). IL1R2 is a decoy receptor for inflammatory interleukin 1 
(IL-1). It acts by sequestering active and inactive IL1, which in turn restricts the 
availability of the ligand for the functional receptor and inhibits its maturation 
(Bossu et al. 1995;Colotta et al. 1994;Subramaniam et al. 2004;Symons et al. 
1995). IL1R1 and IL1R2 are the known receptors of IL1 and cell activation that 
transduce the activation signal which occurs when IL1 binds to cell surface 
IL1R1 in conjunction with IL1R accessory protein (IL1RAP) (Dinarello 2004). 
IL1R2 is known as a potent, specific and natural inhibitor of IL1, but in contrast 
to IL1R1 it has no signalling properties when bound to IL1 (Bossu et al. 
1995;Colotta et al. 1994;Subramaniam et al. 2004;Symons et al. 1995). Over 
expression of IL1R2 has been reported in human uroepithelial cell line (HUC-
1) chronically exposed to arsenite (Chang et al. 2009). Both results show that 
low dose arsenic can induce expression of IL1R2 in HaCaT and HUC-1. IL1R2 
may therefore be a biomarker for chronic exposure to arsenicals. In HUC-1, 
IL1R2 over expression is linked with enhanced expression of Smad-interacting 
protein 1 (SIP-1) and reduced expression of E-cadherin (Chang et al. 2009). 
E-cadherin is a calcium-dependent, epithelial cell adhesion molecule, whose 
reduced expression has been associated with tumour de-differentiation and 
increased lymph node metastasis in clinical studies involving several 
carcinomas (Siitonen et al. 1996). Furthermore, reduced expression levels of 
E-cadherin was associated with moderately and poorly differentiated 
squamous and small cell carcinoma in a limited number of patients with lung 
cancer (Bohm et al. 1994). IL1R2 also improves cell migration (Chang et al. 
2009), which is suggestive of an oncogenic potential of IL1R2. Gene network 
analysis with IL1R2 gene as illustrated in Figure 15, page 90, showed that 
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IL1R2 interacts with IL1RAP, IL1A, IL1B and GLI1 and this agrees with 
previous findings (Bossu et al. 1995;Colotta et al. 1994;Subramaniam et al. 
2004;Symons et al. 1995). But the difference is that this investigation is a 
chronic exposure experiment and the HaCaT was exposed to low 
concentration of ATO (0.5 µg/ml) up to 22 passages. GLI1 proteins 
interconnect with IL1R2 as presented in Figure 15. GLI1 protein was originally 
isolated from human glioblastoma (Kinzler et al. 1987;Saran 2010) and is the 
effector of Hedgehog (Hh) signalling which plays a critical role in 
carcinogenesis. Furthermore, GLI1 was reported to be upregulated in many 
tumours including basal cell carcinomas. Thus, IL1R2 indirectly interacts with 
GLI1, which is the trigger for basal cell cancer (BCC) implicating GLI1 in skin 
carcinogenesis. IL1R2 had been implicated in ulcerative colitis as candidate 
gene which can provide potential important information on the disease 
pathogenesis (Anderson et al. 2011). This receptor binds to two cytokines 
ligands (IL-1 alpha and IL-1 beta) which are active participants in the 
regulation of inflammation, immune responses and haematopoiesis. The 
crystal structures of interleukin receptor family members have been resolved. 
The fold consists of twelve beta-strands which form a six-stranded beta-barrel, 
closed on one side by three beta-hairpin loops. Cys69 and Cys116 are linked 
via a disulphide bond and Pro53 has been built in the cis-conformation 
(Schreuder et al. 1995). The IL1R2 protein was found to possess 11 regulatory 
points for binding of arsenic as a ligand (Kasper et al. 2006). This protein acts 
as a decoy receptor that inhibits the activity of its ligands. For example 
Interleukin 4 (IL4) antagonize the activity of interleukin 1 by inducing the 
expression and release of IL1R2 cytokine (Rennick et al. 1987). Also, arsenic 
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acts as an antagonist in certain pathways leading to cancer (Kim et al. 2010). 
These observations suggest that arsenic will bind on the ILR2 receptor protein 
putative antagonist binding site as an antagonist, thus inducing the expression 
and release of the cytokine gene ILR2 as seen with IL4 above. The induction 
of ILR2 may account for the up regulated expression of IL1R2 gene as 
previously reported (Rennick et al. 1987). Anti-inflammatory response is 
triggered upon binding of arsenic ligand to the Hedgehog (HR) receptor (Kim 
et al. 2010). This arsenic-receptor binding could possibly account for the 
inflammatory reaction seen with patients suffering from arsenic skin cancer.  
Pathway activation within cancer cells has been established for tumours of 
ectodermal or mesodermal origin, primary cancer of the skin, brain and muscle 
(Hahn et al. 1996;Johnson et al. 1996). Ligand dependent activation of some 
pathway ways, for example hedgehog (Hh) signalling, has been associated 
with tumourigenesis. Hence, arsenic may act similarly as a ligand on its 
surrounding cells to elicit secretion of factors that in turn support the growth 
and progression of the cancer cells (Yauch et al. 2008).  
 
The cytokine TNFSF18, which can also be represented as glucocorticoid-
induced tumour necrosis factor receptor-related ligand (GITRL), is a ligand for 
receptor TNFRSF18/AITR/GITR, and it modulates T lymphocyte survival in 
peripheral tissues (Figure 15). TNFSF18 is found in extracellular space and 
integral to membrane (Pruitt et al. 2007). GITRL was significantly over 
expressed with a fold change of more than 174. The glucocorticoid-induced 
tumour necrosis factor receptor-related gene (GITR) is expressed on 
110 
 
regulatory T-cells (Treg), which are CD4+CD25+ lymphocytes. Binding of its 
ligand, GITRL, leads to down-regulation of the biological function of Tregs. A 
defect in Tregs causes a skin condition resembling atopic dermatitis 
(Baumgartner-Nielsen et al. 2006). Soluble forms of GITRL (sGITRL) are 
released by human tumour cells (Baltz et al. 2008) with the determination of 
sGITRL levels might be implemented as a tumour marker in patients. Activated 
keratinocytes are known to engage intraepithelial T-cells through co-
stimulatory molecules, keratinocytes express GITRL and through this 
important co-stimulatory molecule expressed by antigen-presenting cells 
(APCs), they have the potential to influence T-cell numbers in the skin via 
chemokine production and through a direct cell-cell effect on T-cell 
proliferation (Byrne et al. 2009). Sustained arsenic insult could have activated 
the HaCaT keratinocytes, which may lead to an immunotoxigenic reaction as 
reported by Baumgartner-Nielsen et al. (Baumgartner-Nielsen et al. 2006). 
 
Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) (AKR1C3) (Azzarello et al. 2009) was up-regulated up 
to 9.2 folds in this investigation.  Human AKR1C3 is an enzyme involved in 
steroid metabolism as illustrated in Figure 19, page 95. Elevated levels of 
AKR1C3 expression are implicated in leukaemia cell differentiation, prostate 
cancer (in both androgen-dependent and androgen-independent prostate 
cancer), (Fung et al. 2006) endometrial cancer (Rizner et al. 2006) and chronic 
inflammation (Fung et al. 2006). 
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A 3.1 fold change in expression of insulin growth factor-like family member 1 
(IGFL1) was observed. The IGF-like (IGFL1) gene encodes proteins that 
contain 11 conserved cysteine residues at fixed positions including two CC 
motifs (Emtage et al. 2006)]. The knowledge on the biological functions and 
gene interactions of IGFL1 is limited. However, the structure and sequence 
suggest that IGFL proteins are distantly related to the Insulin-like growth 
factors (IGF), a superfamily of growth factors. Both IGFL mRNAs and IGF 
display specific expression patterns; they are expressed in many cancers 
(Emtage et al. 2006).  
 
The human skin is the critical organ of arsenic toxicity because arsenic has a 
strong affinity for the keratin proteins, that are rich in the sulphur containing 
cysteine residues (Ralph 2008) and potentially arsenic-binding proteins based 
on presence of vicinal cysteines (Kitchin et al. 2005).  It was previously 
observed that proteins with abundance of vicinal cysteines could increase 
responsiveness to arsenic-induced keratinocyte carcinogenesis (Isokpehi et al. 
2010). Since IGLF1 encodes proteins rich in cysteine residues, it could be 
playing a vital role in arsenic binding and responsiveness in keratinocytes. 
Further, IGFL1 is associated with embryonic tissue and was observed in 
libraries derived from carcinoma cell lines (Emtage et al. 2006). Therefore, the 
increase in IGFL1 might be involved in cancer development and progression 
and is probably a marker of chronic exposure to ATO.  
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The growth suppressor gene RGS2 accelerate GTPase activity of 
heterotrimeric G proteins, resulting in inactivation of specific signalling 
pathways (De et al. 2000). Down regulation of RGS2 occurred in human 
prostate tumour specimens (Cao et al. 2006) as well as in recurrence and 
metastasis-derived colorectal cancer cell lines (Jiang et al. 2010). In HaCaT 
keratinocyte cells, aberrant expression of RGS2 may aid in the spread of 
cancer or metastasis.  
 
The functional and pathway annotation analysis to identify specific pathways of 
interest from the microarray gene expression datasets was performed using 
Ingenuity Pathway Analysis tool (IPA; Ingenuity Systems, Redwood City, CA).  
Figure 16, page 93 shows the pathways affected by arsenic exposure with the 
most affected being Liver X Receptor /Retinoid X Receptor LXR/RXR pathway 
which are involved in lipid metabolism and immune response (Christoffolete et 
al. 2010;Laffitte et al. 2003). Previously, perturbation of lipid metabolism by 
arsenic toxicity is accessed by the lipid peroxidation assay. The LXRs act as 
molecular sensors of cholesterol levels and respond by inducing processes 
that reduce cholesterol levels (Lehmann et al. 1997).  
 
Ingenuity Pathways Analysis has been used to determine models of biological 
pathways and networks that are significantly represented in the differentially 
expressed (both up and down regulated) genes.  Benjamini-Hochberg 
corrected P ≤ 0.05 is used to select highly significant biological functions and 
pathways represented in the datasets. Benjamini-Hochberg is a type of 
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multiple hypothesis correction that adjusts the p values downwards to account 
for using a null hypothesis process with multiple – often thousands – of 
variables with only a few samples. Confidence is higher when multiple 
hypothesis correction is included (Borch et al. 1992).  
 
AKR1C3 is associated with biological pathways which are involved in thyroid 
hormone response, lipid and carbohydrate metabolism, growth and cell 
proliferation (Figure 19, page 95). AKR1C3 is highly up-regulated, and it is 
obvious from its interaction network that other molecules involved in that 
network are also up-regulated, suggesting that AKR1C3 up-regulation may  
activate the expression of the other molecules in its network. For example, 
activation of 3-beta hydroxysteroid dehydrogenase (3b-hsd) (or prostaglandin 
F synthase) an enzyme which catalyzes the synthesis of progesterone from 
pregnenolone, (Cravioto et al. 1986) might be activating AKR1C3. As 
illustrated in Figure 18, TNFSF18 networks with TNF and a transcription factor 
(Nuclear Factor 1) but expression of TNFSF18 could also trigger the 
expression of IL2 and TNF. Molecules in Green are down-regulated in the 
microarray data. Figure 19, page 95 and Figure 20, page 97, illustrate Nuclear 
Receptor Pathways affected by arsenic exposure as Predicted by Ingenuity 
Pathway Analysis. Liver X Receptor/Retinoid X Receptor (LXR/RXR) Pathway 
is the most affected pathway that is involved in lipid metabolism and immune 
response.  Thyroid Hormone/Retinoid X Receptor (TR/RXR) Pathway is highly 
involved in lipid metabolism, growth and cell proliferation and has been shown 
to be perturbed by ATO. Previous studies however have reported perturbation 
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of Lipid metabolism by arsenic toxicity which influenced the use of lipid 
peroxidation assay to assess arsenic toxicity. LXRs act as molecular sensors 
of cholesterol levels and respond by inducing processes that reduce 
cholesterol levels (Lehmann et al. 1997).  
 
Further analysis of the global microarray gene expression data revealed two 
genes that encode membrane proteins. Interest was focused on these two 
genes, TNFSF18 and IL1R2, as models for studying arsenic modulated 
molecular networks affecting the onset of keratinocyte differentiation. The 
membrane plays a role in determining the function of proteins by modulating 
protein function through localization with the substrate, activator, or 
downstream target, and activation of the protein by a conformational switch 
(Johnson et al. 1999). The rationale for this focus is that membrane localized 
proteins could bind with arsenic at the cell surface and lead to subsequent 
changes in cellular biological pathways. TNFSF18 is a ligand for receptor 
TNFRSF18 and it modulates T lymphocyte survival in peripheral tissues 
playing a vital role in resistance to infection and cancers. TNFSF18 is found in 
extracellular space and integral to membrane (Pruitt et al. 2007). It belongs to 
the TNF ligand super family that contain uniform structural motif, the TNF 
homology domain (THD), which binds to cysteine-rich domains (CRDs) of TNF 
receptors (Bodmer et al. 2002). TNF can exert many of its effects by binding to 
cell membrane receptor. The members of TNF receptor superfamily possess 
an identical characteristic of an extra cellular domain containing two to six 
repeats of cysteine rich motifs (Idriss et al. 2000). It has been suggested that 
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the sequence homology between the CRDs and the DNA-binding 'zinc-fingers' 
may be used to speculate intracellular protein phosphorylation by protein 
kinase C (PKC) (Hommel et al. 1994). IL1R2 also referred to as IL1RB, 
encodes membrane bound proteins known to be crucially involved in immune 
response and it also acts as a decoy receptor for inflammatory interleukin 1 
(IL-1) (Pruitt et al. 2007). The cysteine predictions show that IL1R2 has 9 
cysteine residues, and TNFSF18, 6 cysteine residues (Table 12, page 100).  
 
Disulphide bonds play a key structural role in stabilizing protein conformations. 
Prediction of disulphide bond connectivity facilitates structural and functional 
annotation of proteins (Huang et al. 1999;Skolnick et al. 1997). The cleavage 
of one or more of the disulphide bonds in a protein by arsenic or any other 
catalyst will affect its function (Hogg 2003). Since arsenic is known for its 
preference to bind to cysteine residues, predicting the C-terminal cysteine 
residues may play a critical role in arsenic sensing. Phenylarsine oxide (PAO) 
covalently binds to vicinal protein cysteine thiol groups (He et al. 2009) 
suggesting that the cysteines in IL1R2 and TNFSF18 could be playing a vital 
role in arsenic binding on HaCaT cells. Disulphide-containing proteins are 
attractive drug and diagnostic candidates as their interactions are potent and 
specific. Since arsenic has high affinity to bind to cysteine residues, detecting 
cysteine disulphide bonds could be an arsenic insult marker in proteins 
perturbed by arsenic exposure (Harvey et al. 1998;Harvey 2002). Proteins that 
contain disulphide bonds  are heterogeneous  and participate in  different  
cellular activities  such as  cell-to-cell recognition, cell signalling and cell 
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defence and some of the proteins have direct contact with the membrane (Mas 
et al. 2001).  This membrane binding may promote rearrangement, 
dissociation, or conformational changes within many protein structural 
domains, resulting in an activation or deactivation of their biological activity 
(Johnson et al. 1999;Mas et al. 2001). For some proteins including toxins, their 
biological effects are incited by specific interaction with diverse ion channels 
(Possani et al. 1999)], and cellular receptors within the membrane (Valentin et 
al. 2000). Hains, et al. (Hains et al. 1999) reported membrane involvement in 
toxins biological reaction. Thus, the membrane could also aid in the binding of 
arsenic with membrane localized proteins at the cell surface and help to 
transport arsenic into the cell to trigger of the changes in cellular biological 
pathways associated with arsenic exposure. 
 
A comparison of the different disulphide bond predictions tools showed that all 
the software predicted the same number of cysteines and positions of the 
cysteines in the sequences as expected since it is based on recognition of "C" 
in the sequence. However, there is a discrepancy on the speciation of the 
cysteines residues. The terms oxidized, disulphide bonded and half cysteines 
can be used interchangeably while the other species are termed free cysteines 
or non-disulphide bonded and metal bound or ligand bonded cysteines (Ferre 
et al. 2006;Lippi et al. 2008;Petersen et al. 1999;Yan et al. 2009). The 
prediction of the cysteine bonding state (Matsumura et al. 1989;Richardson 
1981;Vullo et al. 2004), structure and sequence features analysis and 
connectivity patterns classification are integral parts of disulphide bonds 
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characterization (Harrison et al. 1994;Petersen et al. 1999;Yan et al. 2009), 
which could be used in protein identification and classification (Lenffer et al. 
2004). Based on the agreement of software for disulphide bond prediction, we 
prioritized for further research disulphide bond Cys152-Cys207 in IL1R2 and 
disulphide bond Cys24-Cys80 in TNFSF18. The Cys152 and Cys 207 residues 
of IL1R2 and the pair for TNFSF18 cysteines involved in this disulphide bond 
formation are most likely half cysteines (Petersen et al. 1999). Using X-RAY 
crystallography, the following disulphide bonds were confirmed for IL1R2, 28-
116, 50-108, 152-207, 258-326 (Wang et al. 2010) . 
 
The molecular interaction map for IL1B, IL1R2, IL1A, TNFSR18 and TNFSF18 
revealed E2F4 transcription factor as a link between sub-networks (Figure 22, 
page 102). E2F4 controls cell cycle and function in the suppression of 
proliferation-associated genes, and its gene mutation and increased 
expression may be associated with human cancer (Souza et al. 1997). It is 
predominantly expressed at the onset of keratinocyte differentiation (Paramio 
et al. 2000). Further, E2F4 is a promoter of proliferation of human intestinal 
epithelial crypt cells and colorectal cancer cells (Garneau et al. 2009). The 
known predominant expression of E2F4 in the onset of keratinocyte 
differentiation raises the possibility that arsenic perturbation of protein-protein 
interactions that include E2F4 could alter keratinocyte differentiation (Paramio 
et al. 1998). The molecular interaction map predicted Necdin (NDN) as the link 
between E2F4 and IL1A, which binds with IL1R2.  The NDN protein physically 
binds to the carboxyl-terminal transactivation domains of E2F4 (Kobayashi et 
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al. 2002) and the oncogenic activity of the N-terminal of pre-IL1A is attributed 
to the interaction between NDN and the N-terminal of pre-IL1A (Hu et al. 
2003). NDN function in the suppression of proliferation-associated genes and 
its mutation and expression disruption may be associated with human cancer 
(Kawamata et al. 2003).  
 
A member of the TNF receptor associated factor (TRAF2) adapter protein 
family was predicted to interact with E2F4 and TNFSR18 (Figure 22, page 
102). X-ray crystallographic structure of the TRAF domain of TRAF2 revealed 
a trimeric assembly, with each TRAF domain monomer containing a surface 
crevice responsible for binding peptidyl motifs found in the cytosolic domains 
of the TNF family receptors to which TRAF2 is known to bind (McWhirter et al. 
1999). TRAF2 is required for TNF-alpha-mediated activation of MAPK8/JNK 
and NF-kappaB (Pruitt et al. 2007). NF-kappaB functions in immunity however 
the signalling pathways that are involved in its activation have been implicated 
in tumour development (Karin et al. 2002). Inhibition of NF-kappa B activation 
by arsenite through reaction with a critical cysteine in the activation loop of 
Ikappa B kinase has been reported (Kapahi et al. 2000).  
 
Activating Transcription Factor-2 (ATF2) was predicted to interact with both 
E2F4 and IL1B.  ATF2 is a sequence-specific DNA-binding protein that 
belongs to the bZIP family of proteins and has diverse functions in mammalian 
cells. It is activated by stress kinases such as JNK and p38 and responds to 
stress stimuli, by activating gene targets including cyclin A, cyclin D and c-jun, 
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which are involved in oncogenesis in various tissue types (Vlahopoulos et al. 
2008).  Further, ATF2 expression has been correlated with maintenance of a 
cancer cell phenotype. ATF2 plays a pivotal role in melanoma development 
and has been implicated in transcriptional regulation of immediate early genes 
that regulate stress and DNA damage responses (Shah et al. 2010). 
Malfunction of tumour suppressor activities of ATF2 by arsenic may contribute 
to carcinogenesis.  
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Chapter 6 
  Conclusions, Recommendations, Future Studies 
6.1 Conclusion 
The main goal of this research was to determine the mechanism of arsenic 
carcinogenicity in human skin epidermal keratinocytes. The aim was to treat 
the skin cells with a low dose of ATO simulating the natural way that people in 
endemic areas are exposed to inorganic arsenic through drinking water; and to 
determine the genomic changes that occur over a period of time. Two specific 
objectives were used to test the hypothesis that long-term, chronic exposure of 
human epidermal keratinocytes cells (HaCaT cells) to low dose arsenic 
disrupts cellular and molecular processes in keratinocytes. Knowledge of the 
biological pathways and networks of the genes that are significantly expressed 
or altered are crucial in understanding the mechanism of action of arsenic 
carcinogenesis in HaCaT cells.  
 
The first specific objective was to determine cytotoxic and genotoxic effects of 
ATO on HaCaT cells and identify differentially expressed genes in HaCaT 
cells that were chronically exposed to low-dose ATO. The cytotoxic and 
genotoxic effects of ATO on HaCaT cells were determined using MTT assay 
and Comet assays respectively. ATO was observed to be cytotoxic and 
genotoxic to HaCaT keratinocytes. Although such observations have been 
made previously by other researchers, the contrast is that this research is 
centred on chronic exposure, whereas the previous studies focused on acute 
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arsenic exposure. It was also observed that long-term exposure of HaCaT 
cells to a low dose ≤ 1.0 µg/ml of ATO may enhance cell proliferation, while 
higher doses are cytotoxic. A low dose of ATO appears to aid cell growth, but 
concomitantly disrupts the DNA transcription process. 
 
The second aspect of the first specific objective one was to demonstrate 
differentially expressed genes in HaCaT cells chronically exposed to low-dose 
ATO. This objective was achieved with the microarray gene expression 
experiment and subsequent confirmation of the selected differentially 
expressed genes of interest with qRT-PCR. The expression of immune 
response genes such as TNFSF18 (167 fold), IGFL1 (3.1 fold), IL1R2 (5.9 
fold) and AKR1C3 (9.2 fold) and the down regulation of  RGS2 (2.0 fold) 
suggest that chronic arsenic exposure could perturb normal cellular immune 
responses by producing sustained levels of TNF with modulation by an IL-1 
analogue resulting in chronic immunologic insult.  Also, the observed decrease 
in growth inhibiting gene (RGS2) and increase in AKR1C3 may contribute to 
chronic inflammation leading to metaplasia, which may eventually lead to 
carcinogenicity in the skin keratinocytes. Further, increased expression of 
IGFL1 may trigger cancer development and progression in HaCaT 
keratinocytes. 
 
The second specific objective was to identify specific pathways from the gene 
expression datasets of HaCaT exposed to ATO. This objective also included 
the use of bioinformatics tools to perform functional and pathway annotation 
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to identify specific pathways of interest from the gene expression datasets.  
High-throughput gene transcription assays such as DNA microarrays allows 
for the identification of biological pathways affected by arsenic that lead to 
initiation and progression of skin cancer. Pathway analyses of the differentially 
expressed genes were also performed, and qRT-PCR confirmed the gene 
expression results. In the functional and pathway annotation analysis, the 
Liver X Receptor/Retinoid X Receptor LXR/RXR pathway commonly involved 
in lipid metabolism and immune response was the most affected by arsenic 
exposure.  
 
The disulphide bond prediction and molecular network analyses on selected 
up-regulated genes encoding membrane proteins were performed. The 
prediction identified cysteine residues that are potential markers for arsenic-
binding in two up-regulated genes (IL1R2 and TNFSF18). From the arsenic 
protein interaction, it may be suggested that arsenic functions as a ligand in 
the pathway leading to skin cancer. It attaches to the antagonist binding site 
on the IL1R2 protein, activating its pathway. Arsenic pathogenesis may involve 
both pathway activation and transcription.   
 
Further, reconstructed molecular networks revealed interconnections to E2F4, 
an oncogenic transcription factor, predominantly expressed at the onset of 
keratinocyte differentiation. This report provides insights into previously 
unknown gene markers that may explain the mechanisms of arsenic-induced 
dermal disorders including skin cancer. 
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A combination of microarray, gene functional annotation data and qRT-PCR 
has been used to identify genes that are differentially expressed in HaCaT cell 
in response to chronic, low dose ATO. Further research will be to find out the 
details on the roles of each gene perturbed by arsenic exposure in 
keratinocytes. 
 
6.2 Significance of the Study 
This research has generated microarray data on global alteration of gene 
expression in HaCaT keratinocyte in response to ATO. A set of genes has 
been identified for more possible focal points of interest in skin carcinogenesis 
especially the interactions of arsenic with encoded proteins having known 
roles in skin physiology. Gene lists and pathways of arsenic toxicity to HaCaT 
cells were generated. Also, models of interaction of arsenic with cysteine 
residues (regulatory residues for protein interaction with arsenic) were 
developed. 
 
6.3 Recommendations 
Bioinformatics analyses and visual analytics are very essential in the analysis 
of high troughput datasets to discover interesting patterns of potential 
biological significance in skin cancer induced by arsenicals. Also, investigation 
of the perturbation of noncoding RNAs, such as miRNA, induced by arsenic in 
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HaCaT may lead to more discoveries of arsenic mechanisms of action. Since 
abnormal pigmentation is a common sign of chronic arsenic toxicity, further 
investigation to identify genes enriched for melanosomes (melanin-pigment 
bearing organelles) could be helpful to understand the molecular basis of 
aberrant pigmentation.  
 
6.4 Future Studies 
Further studies are planned to validate the gene expression results using 
enzymatic and immunochemistry assays, since arsenic toxicification was 
generated. Reactive oxygen species (ROS) assays would be performed to 
measure NADPH oxidation, and glutathione synthetase (GSS) oxidation and 
reduction. Also, Western Blot against an anti ROS protein would be 
performed. Further, peoteomics studies will be undertaken to correlate the 
gene expression result with protein expression. Protein data bases and 
bioinformatics tools would be used for the data analysis. The adoption of a 
new proteome data analysis strategies and combined information from 
proteome and transcriptome can enhance the insights gained from either type 
of data alone. 
 
A more focused research is needed on the set of genes identified in this study 
to determine the interactions of arsenic with the encoded proteins with known 
roles in skin physiology. Additional bioinformatics analyses and visual analytics 
will be performed on the datasets to unravel interesting patterns of potential 
125 
 
biological significance in skin cancer-induced by arsenicals. For instance, a 
molecular network construction for arsenic upregulated genes TNFSF18 and 
IL1R2 revealed subnetwork interconnections to E2F4, an oncogenic 
transcription factor, predominantly expressed at the onset of keratinocyte 
differentiation. Visual analytics integration of gene information sources helped 
identify RAC1, a GTP binding protein, and TFRC, an iron uptake protein as 
prioritized arsenic-perturbed protein targets for biological processes leading to 
skin hyperpigmentation RAC1 regulates the formation of dendrites that transfer 
melanin from melanocytes to neighboring keratinocytes. Increased melanocyte 
dendricity is correlated with hyperpigmentation. TFRC is a key determinant of 
the amount and location of iron in the epidermis. Aberrant TFRC expression 
could impair cutaneous iron metabolism leading to abnormal pigmentation 
seen in some humans exposed to arsenicals (Isokpehi 2012). The application 
of miRNA technology will be necessary to study more on the interaction 
between arsenic, keratinocytes and melanocytes and TFRC induction in skin 
carcinogenesis process.  
 
Environmental management of arsenic is also crucial. and this could benefit 
from determining the presence of genes known to metabolize arsenic 
containing compounds. Understanding arsenic metabolism by microbial 
communities in the environment and in human hosts could lead to novel 
strategies to prevent and manage arsenic-induced diseases. Determining the 
presence of genes known to metabolize arsenic containing compounds will 
contribute to the knowledge on the role of human microbial flora in arsenic 
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metabolism. Furthermore, revealing the identity and function of microbial 
communities (microbiome) in human body habitats, using DNA sequencing 
technologies holds promise for dynamic assessment of health status and 
disease management. This microbiome knowledge could further be used to 
characterize the relationship between genetic variation and disease 
susceptibility.  
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Appendix 
Quantitative PCR Analysis Report  
 
Relative Quantification: using GAPDH as endogenous control 
 
Sample: human total RNA 
 H1, H2, H3, H4, As1, As2, As3, As4 
 
Target Gene:  
RGS2, PPP1R13B, MKNK1, TM4SF4, AKR1C3, TMEM70, TNFSF18, IGFL1, 
IL1R2, PCSK1 
 
Materials and methods: 
Primer Sequence 
Human RGS2-F GAATTCTGGCTGGCCTGTGA 
Human RGS2-R ATGTTTATCTCTTTTGGAGCTTCCTT 
Human PPP1R13B-F GCCACACCACCTAAGAATTACCA 
Human PPP1R13B-R GAGAGGTTGAACCCGAAGGTAAA 
Human MKNK1-F CAACTCCTGTACCCCCATAACC 
Human MKNK1-R TGGCCTGGTCCGTGAAGA 
Human TM4SF4-F TGGGCCTGAAGAACAATGACT 
Human TM4SF4-R CAAGAATCCAACCACAGCAAATAT 
Human AKR1C3-F GGAGAAGTGTAAGGATGCAGGATT 
Human AKR1C3-R GTACTTGAGTCCTGGCTTGTTGAG 
Human TMEM70-F AAGGCATGGGATCGTTTCC 
Human TMEM70-R ACTCCTGGCTCAATACTGATGGA 
Human TNFSF18-F AGCCCTGTATGGCTAAGTTTGG 
Human TNFSF18-R GCCATTCTGAAGTATCTCCAGCTT 
Human IGFL1-F CATCGTAGCTGTCTTTGCCATT 
Human IGFL1-R TGGCTGGCACAGCATCAG 
Human IL1R2-F CACTACGCACCACAGTCAAGGA 
Human IL1R2-R ATCCATATTCCCCCCAAAACC 
Human PCSK1-F CCTGGAAGCAAACCCAAATC 
Human PCSK1-R ATCCAAATCGACTATTCACCATCA 
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Results (H1 as calibrator): 
 
Relative quantitation using the comparative CT method 
 
 
 
1. RGS2 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 27.78±0.11 16.24±0.02 11.53±0.11 0.00±0.11 1.00 
H2 27.75±0.06 16.07±0.01 11.68±0.06 0.15±0.06 0.90 
H3 27.38±0.10 16.05±0.02 11.33±0.10 -0.21±0.10 1.15 
H4 27.99±0.02 16.38±0.03 11.62±0.04 0.09±0.04 0.94 
As1 28.89±0.10 16.38±0.03 12.51±0.12 0.98±0.12 0.51 
As2 28.36±0.06 15.94±0.04 12.42±0.07 0.89±0.07 0.54 
As3 28.82±0.15 16.14±0.02 12.67±0.15 1.14±0.15 0.45 
As4 28.41±0.04 15.93±0.03 12.48±0.05 0.95±0.05 0.52 
      
 
 
 
 
Amplification plot: 
 
 
 
 
 
Gene expression plot: 
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2. PPP1R13B 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 26.64±0.07 16.24±0.02 10.39±0.07 0.00±0.07 1.00 
H2 26.55±0.03 16.07±0.01 10.48±0.03 0.09±0.03 0.94 
H3 26.19±0.05 16.05±0.02 10.14±0.05 -0.25±0.05 1.19 
H4 25.97±0.04 16.38±0.03 9.60±0.05 -0.80±0.05 1.74 
As1 27.14±0.05 16.38±0.03 10.76±0.08 0.36±0.08 0.78 
As2 26.70±0.03 15.94±0.04 10.76±0.05 0.37±0.05 0.77 
As3 27.08±0.06 16.14±0.02 10.94±0.07 0.54±0.07 0.69 
As4 25.95±0.04 15.93±0.03 10.02±0.05 =.37±0.05 1.29 
      
 
 
 
 
Amplification plot: 
 
 
 
 
 
Gene expression plot: 
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3. MKNK1 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 24.93±0.05 16.24±0.02 8.69±0.05 1.00±0.05 1.00 
H2 24.73±0.03 16.07±0.01 8.66±0.03 -0.03±0.03 1.02 
H3 24.43±0.07 16.05±0.02 8.38±0.07 -0.31±0.07 1.24 
H4 24.49±0.05 16.38±0.03 8.12±0.06 -0.57±0.06 1.48 
As1 25.26±0.06 16.38±0.03 8.88±0.09 0.20±0.09 0.87 
As2 24.79±0.03 15.94±0.04 8.85±0.05 0.17±0.05 0.89 
As3 25.18±0.05 16.14±0.02 9.04±0.05 0.35±0.05 0.78 
As4 23.99±0.02 15.93±0.03 8.06±0.04 -0.63±0.04 1.54 
      
 
 
 
Amplification plot: 
 
 
 
 
 
Gene expression plot: 
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4. TM4SF4 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 Undet. 16.24±0.02 Undet Undet Undet 
H2 35.90±0.07 16.07±0.01 19.83±0.07 Undet Undet 
H3 Undet 16.05±0.02 Undet Undet Undet 
H4 Undet 16.38±0.03 Undet Undet Undet 
As1 Undet 16.38±0.03 Undet Undet Undet 
As2 Undet 15.94±0.04 Undet Undet Undet 
As3 Undet 16.14±0.02 Undet Undet Undet 
As4 Undet 15.93±0.03 Undet Undet Undet 
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5. AKR1C3 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 23.15±0.05 16.24±0.02 6.90±0.05 0.00±0.05 1.00 
H2 23.22±0.06 16.07±0.01 7.15±0.07 0.25±0.07 0.84 
H3 22.86±0.11 16.05±0.02 6.81±0.11 -0.10±0.11 1.07 
H4 23.08±0.03 16.38±0.03 6.70±0.04 -0.20±0.04 1.15 
As1 20.29±0.04 16.38±0.03 3.91±0.08 -2.99±0.08 7.94 
As2 19.55±0.06 15.94±0.04 3.61±0.07 -3.29±0.07 9.81 
As3 19.99±0.12 16.14±0.02 3.84±0.12 -3.06±0.12 8.34 
As4 19.39±0.02 15.93±0.03 3.46±0.04 -3.44±0.04 10.87 
      
 
 
 
Amplification plot: 
 
 
 
 
Gene expression plot: 
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6. TMEM70 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 20.88±0.14 16.24±0.02 4.64±0.14 0.00±0.14 1.00 
H2 20.21±0.04 16.07±0.01 4.14±0.05 -0.49±0.05 1.41 
H3 20.30±0.12 16.05±0.02 4.25±0.12 -0.39±0.12 1.31 
H4 19.95±0.06 16.38±0.03 3.57±0.07 -1.07±0.07 2.09 
As1 21.00±0.01 16.38±0.03 4.62±0.07 -0.02±0.07 1.01 
As2 19.85±0.10 15.94±0.04 3.91±0.11 -0.73±0.11 1.66 
As3 20.74±0.32 16.14±0.02 1.60±0.32 -0.04±0.32 1.03 
As4 19.29±0.03 15.93±0.03 3.37±0.04 -1.27±0.04 2.41 
      
 
 
 
 
Amplification plot: 
 
 
 
 
Gene expression plot: 
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7. TNFSF18 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 31.84±0.04 16.24±0.02 15.60±0.04 0.00±0.04 1.00 
H2 31.07±0.04 16.07±0.01 15.00±0.04 -0.60±0.04 1.52 
H3 31.05±0.08 16.05±0.02 15.00±0.08 -0.61±0.08 1.52 
H4 31.62±0.09 16.38±0.03 15.25±0.10 -0.36±0.10 1.28 
As1 24.53±0.05 16.38±0.03 8.16±0.08 -7.45±0.08 174.47 
As2 23.46±0.02 15.94±0.04 7.52±0.04 -8.09±0.04 271.53 
As3 23.93±0.02 16.14±0.02 7.79±0.03 -7.82±0.03 225.43 
As4 23.64±0.03 15.93±0.03 7.71±0.05 -7.89±0.05 237.67 
 
 
 
 
Amplification plot: 
 
 
 
 
 
Gene expression plot: 
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8. IGFL1 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 26.85±0.08 16.24±0.02 10.61±0.09 0.00±0.09 1.00 
H2 26.70±0.01 16.07±0.01 10.63±0.02 0.02±0.02 0.99 
H3 26.70±0.04 16.05±0.02 10.65±0.05 0.04±0.05 0.97 
H4 26.45±0.02 16.38±0.03 10.08±0.04 -0.53±0.04 1.44 
As1 26.14±0.01 16.38±0.03 9.76±0.07 -0.84±0.07 1.79 
As2 25.04±0.12 15.94±0.04 9.10±0.13 -1.51±0.13 2.85 
As3 25.61±0.05 16.14±0.02 9.47±0.05 -1.14±0.05 2.20 
As4 23.12±0.02 15.93±0.03 7.19±0.04 -3.41±0.04 10.66 
 
 
 
 
Amplification plot: 
 
 
 
 
Gene expression plot: 
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9. IL1R2 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 30.90±0.02 16.24±0.02 14.66±0.02 0.00±0.02 1.00 
H2 29.71±0.09 16.07±0.01 13.64±0.09 -1.02±0.09 2.03 
H3 29.88±0.05 16.05±0.02 13.83±0.05 -0.83±0.05 1.78 
H4 30.21±0.16 16.38±0.03 13.84±0.16 -0.82±0.16 1.76 
As1 28.11±0.04 16.38±0.03 11.73±0.08 -2.93±0.08 7.60 
As2 27.14±0.03 15.94±0.04 11.21±0.05 -3.45±0.05 10.94 
As3 27.86±0.12 16.14±0.02 11.72±0.12 -2.94±0.12 7.66 
As4 27.03±0.06 15.93±0.03 11.11±0.07 -3.55±0.07 11.71 
 
 
 
 
Amplification plot: 
 
 
 
 
 
 
Gene expression plot: 
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10. PCSK1 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 33.55±0.18 16.24±0.02 17.31±0.18 0.00±0.18 1.00 
H2 32.90±0.24 16.07±0.01 16.83±0.24 -0.48±0.24 1.40 
H3 33.05±0.04 16.05±0.02 17.00±0.04 -0.32±0.04 1.24 
H4 32.46±0.15 16.38±0.03 16.08±0.15 -1.23±0.15 2.34 
As1 34.77±1.23 16.38±0.03 18.39±1.24 1.08±1.24 0.47 
As2 34.84±0.20 15.94±0.04 18.90±0.20 1.59±0.20 0.33 
As3 34.13 16.14±0.02 17.98 0.67 0.63 
As4 34.24±0.30 15.93±0.03 18.31±0.30 1.00±0.30 0.50 
      
 
 
 
Amplification plot: 
 
 
 
 
Gene expression plot: 
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Quantitative PCR Analysis Report with GUSB as Endogenous Control 
 
  
Sample: human total RNA 
 H1, H2, H3, H4, As1, As2, As3, As4 
 
Target Gene: 
RGS2, PPP1R13B, MKNK1, TM4SF4, AKR1C3, TMEM70, TNFSF18, 
IGFL1,  
IL1R2, PCSK1, KLK7, GUSB 
 
 Primer Sequence 
 
Human GUSB-F TGATCGCTCACACCAAATCC 
Human GUSB-R CCCCTTGTCTGCTGCATAGTTA 
Human KLK7-F CTCATGTGCGTGGATGTCAAG 
Human KLK7-R GCGCACAGCATGGAATTTT 
 
Result 1 (using GAPDH as endogenous control): 
 
Relative quantitation using the comparative CT method 
 
 
11. GUSB 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 22.73±0.06 17.33±0.02 5.40±0.07 0.00±0.07 1.00 
H2 22.85±0.11 17.14±0.02 5.70±0.12 0.29±0.12 0.81 
H3 22.96±0.13 17.30±0.04 5.66±0.14 0.26±0.14 0.83 
H4 22.79±0.03 17.28±0.01 5.51±0.03 0.10±0.03 0.92 
As1 23.20±0.09 17.42±0.08 5.78±0.12 0.37±0.12 0.77 
As2 22.87±0.01 16.93±0.04 5.94±0.05 0.53±0.05 0.68 
As3 23.30±0.09 17.32±0.01 5.98±0.09 0.58±0.09 0.66 
As4 22.94±0.04 17.16±0.01 5.77±0.04 0.37±0.04 0.77 
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Amplification plot: 
 
 
 
 
Gene expression plot: 
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12. KLK7 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 24.86±0.04 17.33±0.02 7.52±0.05 0.00±0.05 1.00 
H2 24.53±0.02 17.14±0.02 7.39±0.03 -0.13±0.03 1.09 
H3 24.56±0.04 17.30±0.04 7.26±0.06 -0.26±0.06 1.19 
H4 24.48±0.05 17.28±0.01 7.20±0.05 -0.32±0.05 1.25 
As1 24.81±0.09 17.42±0.08 7.39±0.13 -0.13±0.13 1.09 
As2 24.20±0.05 16.93±0.04 7.26±0.07 -0.26±0.07 1.19 
As3 24.78±0.04 17.32±0.01 7.46±0.04 -0.06±0.04 1.04 
As4 23.54±0.04 17.16±0.01 6.37±0.04 -1.15±0.04 2.21 
      
 
 
 
Amplification plot: 
 
  
 
 
Gene expression plot: 
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Result 2 (using GUSB as endogenous control): 
Relative quantitation using the comparative CT method 
 
1. RGS2 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 27.78±0.11 16.24±0.02 11.53±0.11 0.00±0.11 1.00 1.00 
H2 27.75±0.06 16.07±0.01 11.68±0.06 0.15±0.06 0.90 1.11 
H3 27.38±0.10 16.05±0.02 11.33±0.10 -0.21±0.10 1.15 1.38 
H4 27.99±0.02 16.38±0.03 11.62±0.04 0.09±0.04 0.94 1.02 
As1 28.89±0.10 16.38±0.03 12.51±0.12 0.98±0.12 0.51 0.66 
As2 28.36±0.06 15.94±0.04 12.42±0.07 0.89±0.07 0.54 0.79 
As3 28.82±0.15 16.14±0.02 12.67±0.15 1.14±0.15 0.45 0.68 
As4 28.41±0.04 15.93±0.03 12.48±0.05 0.95±0.05 0.52 0.67 
       
 
 
 
2. PPP1R13B 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 26.64±0.07 16.24±0.02 10.39±0.07 0.00±0.07 1.00 1.00 
H2 26.55±0.03 16.07±0.01 10.48±0.03 0.09±0.03 0.94 1.16 
H3 26.19±0.05 16.05±0.02 10.14±0.05 -0.25±0.05 1.19 1.43 
H4 25.97±0.04 16.38±0.03 9.60±0.05 -0.80±0.05 1.74 1.89 
As1 27.14±0.05 16.38±0.03 10.76±0.08 0.36±0.08 0.78 1.01 
As2 26.70±0.03 15.94±0.04 10.76±0.05 0.37±0.05 0.77 1.13 
As3 27.08±0.06 16.14±0.02 10.94±0.07 0.54±0.07 0.69 1.04 
As4 25.95±0.04 15.93±0.03 10.02±0.05 0.37±0.05 1.29 1.67 
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3. MKNK1 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 24.93±0.05 16.24±0.02 8.69±0.05 1.00±0.05 1.00 1.00 
H2 24.73±0.03 16.07±0.01 8.66±0.03 -0.03±0.03 1.02 1.25 
H3 24.43±0.07 16.05±0.02 8.38±0.07 -0.31±0.07 1.24 1.49 
H4 24.49±0.05 16.38±0.03 8.12±0.06 -0.57±0.06 1.48 1.60 
As1 25.26±0.06 16.38±0.03 8.88±0.09 0.20±0.09 0.87 1.12 
As2 24.79±0.03 15.94±0.04 8.85±0.05 0.17±0.05 0.89 1.30 
As3 25.18±0.05 16.14±0.02 9.04±0.05 0.35±0.05 0.78 1.18 
As4 23.99±0.02 15.93±0.03 8.06±0.04 -0.63±0.04 1.54 2.00 
       
 
 
 
 
4. TM4SF4 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
H1 Undet. 16.24±0.02 Undet Undet Undet 
H2 35.90±0.07 16.07±0.01 19.83±0.07 Undet Undet 
H3 Undet 16.05±0.02 Undet Undet Undet 
H4 Undet 16.38±0.03 Undet Undet Undet 
As1 Undet 16.38±0.03 Undet Undet Undet 
As2 Undet 15.94±0.04 Undet Undet Undet 
As3 Undet 16.14±0.02 Undet Undet Undet 
As4 Undet 15.93±0.03 Undet Undet Undet 
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5. AKR1C3 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 23.15±0.05 16.24±0.02 6.90±0.05 0.00±0.05 1.00 1.00 
H2 23.22±0.06 16.07±0.01 7.15±0.07 0.25±0.07 0.84 1.03 
H3 22.86±0.11 16.05±0.02 6.81±0.11 -0.10±0.11 1.07 1.28 
H4 23.08±0.03 16.38±0.03 6.70±0.04 -0.20±0.04 1.15 1.25 
As1 20.29±0.04 16.38±0.03 3.91±0.08 -2.99±0.08 7.94 10.31 
As2 19.55±0.06 15.94±0.04 3.61±0.07 -3.29±0.07 9.81 14.42 
As3 19.99±0.12 16.14±0.02 3.84±0.12 -3.06±0.12 8.34 12.63 
As4 19.39±0.02 15.93±0.03 3.46±0.04 -3.44±0.04 10.87 14.11 
       
 
 
 
 
6. TMEM70 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 20.88±0.14 16.24±0.02 4.64±0.14 0.00±0.14 1.00 1.00 
H2 20.21±0.04 16.07±0.01 4.14±0.05 -0.49±0.05 1.41 1.74 
H3 20.30±0.12 16.05±0.02 4.25±0.12 -0.39±0.12 1.31 1.57 
H4 19.95±0.06 16.38±0.03 3.57±0.07 -1.07±0.07 2.09 2.27 
As1 21.00±0.01 16.38±0.03 4.62±0.07 -0.02±0.07 1.01 1.31 
As2 19.85±0.10 15.94±0.04 3.91±0.11 -0.73±0.11 1.66 2.44 
As3 20.74±0.32 16.14±0.02 1.60±0.32 -0.04±0.32 1.03 1.56 
As4 19.29±0.03 15.93±0.03 3.37±0.04 -1.27±0.04 2.41 3.12 
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7. TNFSF18 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 31.84±0.04 16.24±0.02 15.60±0.04 0.00±0.04 1.00 1.00 
H2 31.07±0.04 16.07±0.01 15.00±0.04 -0.60±0.04 1.52 1.87 
H3 31.05±0.08 16.05±0.02 15.00±0.08 -0.61±0.08 1.52 1.83 
H4 31.62±0.09 16.38±0.03 15.25±0.10 -0.36±0.10 1.28 1.39 
As1 24.53±0.05 16.38±0.03 8.16±0.08 -7.45±0.08 174.47 226.58 
As2 23.46±0.02 15.94±0.04 7.52±0.04 -8.09±0.04 271.53 399.30 
As3 23.93±0.02 16.14±0.02 7.79±0.03 -7.82±0.03 225.43 341.56 
As4 23.64±0.03 15.93±0.03 7.71±0.05 -7.89±0.05 237.67 308.66 
       
 
 
 
 
8. IGFL1 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 26.85±0.08 16.24±0.02 10.61±0.09 0.00±0.09 1.00 1.00 
H2 26.70±0.01 16.07±0.01 10.63±0.02 0.02±0.02 0.99 1.22 
H3 26.70±0.04 16.05±0.02 10.65±0.05 0.04±0.05 0.97 1.16 
H4 26.45±0.02 16.38±0.03 10.08±0.04 -0.53±0.04 1.44 1.56 
As1 26.14±0.01 16.38±0.03 9.76±0.07 -0.84±0.07 1.79 2.32 
As2 25.04±0.12 15.94±0.04 9.10±0.13 -1.51±0.13 2.85 4.19 
As3 25.61±0.05 16.14±0.02 9.47±0.05 -1.14±0.05 2.20 3.33 
As4 23.12±0.02 15.93±0.03 7.19±0.04 -3.41±0.04 10.66 13.84 
       
 
  
180 
 
9. IL1R2 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 30.90±0.02 16.24±0.02 14.66±0.02 0.00±0.02 1.00 1.00 
H2 29.71±0.09 16.07±0.01 13.64±0.09 -1.02±0.09 2.03 2.50 
H3 29.88±0.05 16.05±0.02 13.83±0.05 -0.83±0.05 1.78 2.14 
H4 30.21±0.16 16.38±0.03 13.84±0.16 -0.82±0.16 1.76 1.91 
As1 28.11±0.04 16.38±0.03 11.73±0.08 -2.93±0.08 7.60 9.87 
As2 27.14±0.03 15.94±0.04 11.21±0.05 -3.45±0.05 10.94 16.08 
As3 27.86±0.12 16.14±0.02 11.72±0.12 -2.94±0.12 7.66 11.60 
As4 27.03±0.06 15.93±0.03 11.11±0.07 -3.55±0.07 11.71 15.20 
       
 
 
 
 
10. PCSK1 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 33.55±0.18 16.24±0.02 17.31±0.18 0.00±0.18 1.00 1.00 
H2 32.90±0.24 16.07±0.01 16.83±0.24 -0.48±0.24 1.40 1.72 
H3 33.05±0.04 16.05±0.02 17.00±0.04 -0.32±0.04 1.24 1.49 
H4 32.46±0.15 16.38±0.03 16.08±0.15 -1.23±0.15 2.34 2.54 
As1 34.77±1.23 16.38±0.03 18.39±1.24 1.08±1.24 0.47 0.61 
As2 34.84±0.20 15.94±0.04 18.90±0.20 1.59±0.20 0.33 0.48 
As3 34.13 16.14±0.02 17.98 0.67 0.63 0.95 
As4 34.24±0.30 15.93±0.03 18.31±0.30 1.00±0.30 0.50 0.64 
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11. KLK7 
Sample Target 
Average CT 
GAPDH 
Average CT 
ΔCT 
Target - GAPDH 
ΔΔCT 
ΔCT-ΔCT,A10 
Rel. to 
A10 
(GAPDH as 
control) 
Rel. to 
A10 
(GUSB as 
control) 
H1 24.86±0.04 17.33±0.02 7.52±0.05 0.00±0.05 1.00 1.00 
H2 24.53±0.02 17.14±0.02 7.39±0.03 -0.13±0.03 1.09 1.34 
H3 24.56±0.04 17.30±0.04 7.26±0.06 -0.26±0.06 1.19 1.43 
H4 24.48±0.05 17.28±0.01 7.20±0.05 -0.32±0.05 1.25 1.35 
As1 24.81±0.09 17.42±0.08 7.39±0.13 -0.13±0.13 1.09 1.41 
As2 24.20±0.05 16.93±0.04 7.26±0.07 -0.26±0.07 1.19 1.75 
As3 24.78±0.04 17.32±0.01 7.46±0.04 -0.06±0.04 1.04 1.57 
As4 23.54±0.04 17.16±0.01 6.37±0.04 -1.15±0.04 2.21 2.87 
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